instruction,input,output,task_type,source,text
"As a pharmaceutical researcher, analyze this compound:
CCCCCCCC/C=C/CCCCCCCCN
DECTAFLUR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.98 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCCC/C=C/CCCCCCCCN
DECTAFLUR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.98 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Drug Name: MISOPROSTOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Drug Name: MISOPROSTOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ccncc1N.O=P(O)(O)O
AMIFAMPRIDINE PHOSPHATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 207.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ccncc1N.O=P(O)(O)O
AMIFAMPRIDINE PHOSPHATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 207.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Name: TAURODEOXYCHOLIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 499.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Name: TAURODEOXYCHOLIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 499.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNS(=O)(=O)c1cc(OC)c(OC)c(C(=O)NCC2CCCN2C)c1
Drug Name: SULVERAPRIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNS(=O)(=O)c1cc(OC)c(OC)c(C(=O)NCC2CCCN2C)c1
Drug Name: SULVERAPRIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
Name: FOSRAVUCONAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 547.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
Name: FOSRAVUCONAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 547.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NC(=O)c1cccnc1
NIACINAMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 122.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NC(=O)c1cccnc1
NIACINAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 122.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CCC/C=C(\c1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1)c1cccnc1
SAMIXOGREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 485.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CCC/C=C(\c1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1)c1cccnc1
SAMIXOGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 485.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccc(C(C)C)cc1
MIPROXIFENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.83 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccc(C(C)C)cc1
MIPROXIFENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.83 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl
BUCINDOLOL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl
BUCINDOLOL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CNC(=O)ON(C(C)=O)C(=O)NC",,"## Molecular Property Analysis: CARACEMIDE

### Structure
```
CNC(=O)ON(C(C)=O)C(=O)NC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.55 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 87.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CNC(=O)ON(C(C)=O)C(=O)NC
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CARACEMIDE

### Structure
```
CNC(=O)ON(C(C)=O)C(=O)NC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.55 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 87.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2",,"## Molecular Property Analysis: TRIAZOLAM

### Structure
```
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 343.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.23 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 43.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TRIAZOLAM

### Structure
```
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 343.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.23 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 43.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1
Drug Name: ATACIGUAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1
Drug Name: ATACIGUAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO
RIVICICLIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO
RIVICICLIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CCC(C(C)C)C(O)C1
Candidate Name: MENTHOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 156.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CCC(C(C)C)C(O)C1
Candidate Name: MENTHOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 156.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CC(Oc1ccccc1)Oc1ccccc1
MEDIFOXAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CC(Oc1ccccc1)Oc1ccccc1
MEDIFOXAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1
PYRIMETHAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1
PYRIMETHAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1nc(-c2ccccc2)c2cc(Cl)ccc2n1CC(F)(F)F
Drug Name: FLUQUAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 338.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1nc(-c2ccccc2)c2cc(Cl)ccc2n1CC(F)(F)F
Drug Name: FLUQUAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 338.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 328.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 328.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC(=O)c1ccc(N)cc1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC(=O)c1ccc(N)cc1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CCCC(=O)C1CCCCC1)[C@@H](C)Cc1ccc(OC)cc1
Drug Name: DEXSECOVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CCCC(=O)C1CCCCC1)[C@@H](C)Cc1ccc(OC)cc1
Drug Name: DEXSECOVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
Candidate Name: TORSEMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
Candidate Name: TORSEMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1c([N+](=O)[O-])cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(Br)cc1C(F)(F)F
Name: BROMOXANIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.94 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1c([N+](=O)[O-])cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(Br)cc1C(F)(F)F
Name: BROMOXANIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.94 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1CCC[C@H]1c1cccnc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1CCC[C@H]1c1cccnc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(-c3ccc(F)cc3)nc(=O)n(C(C)C)c2c1
Candidate Name: FLUPROQUAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(-c3ccc(F)cc3)nc(=O)n(C(C)C)c2c1
Candidate Name: FLUPROQUAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
GANAPLACIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
GANAPLACIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl
Name: BMS-794833",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl
Name: BMS-794833
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1",,"## Molecular Property Analysis: CHLORDIAZEPOXIDE

### Structure
```
CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 299.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.95 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 50.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CHLORDIAZEPOXIDE

### Structure
```
CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 299.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.95 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 50.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)NCC(O)c1ccc(O)c(CS(C)(=O)=O)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)NCC(O)c1ccc(O)c(CS(C)(=O)=O)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
OCc1ccccc1",,"## Molecular Property Analysis: BENZYL ALCOHOL

### Structure
```
OCc1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 108.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
OCc1ccccc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BENZYL ALCOHOL

### Structure
```
OCc1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 108.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
N[C@H](CC(=O)O)C(=O)O",,"## Molecular Property Analysis: D-ASPARTATE

### Structure
```
N[C@H](CC(=O)O)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 133.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -1.13 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 100.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
N[C@H](CC(=O)O)C(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: D-ASPARTATE

### Structure
```
N[C@H](CC(=O)O)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 133.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -1.13 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 100.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(C)NCC(O)c1cc(O)cc(O)c1
TERBUTALINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(C)NCC(O)c1cc(O)cc(O)c1
TERBUTALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNCCCN1c2ccccc2CCc2ccccc21
DESIPRAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNCCCN1c2ccccc2CCc2ccccc21
DESIPRAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)[nH]c(N)nc21
Drug Name: ENTECAVIR ANHYDROUS",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)[nH]c(N)nc21
Drug Name: ENTECAVIR ANHYDROUS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(NO)c1cccnc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(NO)c1cccnc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(-c2nc3ccccc3[nH]2)cc1
Compound_EXP002",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(-c2nc3ccccc3[nH]2)cc1
Compound_EXP002
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC[N+](CC)(CC)CC.[Br-]
Candidate Name: TETRYLAMMONIUM BROMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC[N+](CC)(CC)CC.[Br-]
Candidate Name: TETRYLAMMONIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(OCCN1CCCCC1)C1(C2CCCCC2)CCCCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(OCCN1CCCCC1)C1(C2CCCCC2)CCCCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
Drug Name: REDAFAMDASTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 455.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
Drug Name: REDAFAMDASTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 455.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1
ARHALOFENATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1
ARHALOFENATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc(C(CCN(C)C)c2ccccc2)cc1
TOLPROPAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc(C(CCN(C)C)c2ccccc2)cc1
TOLPROPAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O
Name: QUINIDINE SULFATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 783.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O
Name: QUINIDINE SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 783.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCNC[C@@H]1OC
TICALOPRIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCNC[C@@H]1OC
TICALOPRIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl
Drug Name: NEFAZODONE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl
Drug Name: NEFAZODONE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2
TINORIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2
TINORIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCN1C(=O)[C@@H]2C(=O)N(CCCCN3CCN(c4ccccc4OC)CC3)C(=O)[C@H](C1=O)C2(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCN1C(=O)[C@@H]2C(=O)N(CCCCN3CCN(c4ccccc4OC)CC3)C(=O)[C@H](C1=O)C2(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O
Name: SAQUINAVIR MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 166.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O
Name: SAQUINAVIR MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 166.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
NCC(=O)O",,"## Molecular Property Analysis: GLYCINE

### Structure
```
NCC(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 75.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.97 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 63.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
NCC(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GLYCINE

### Structure
```
NCC(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 75.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.97 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 63.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",,"## Molecular Property Analysis: CYTARABINE

### Structure
```
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 243.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -2.56 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 130.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CYTARABINE

### Structure
```
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 243.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -2.56 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 130.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CCC1(C(C)C)C(=O)NC(=O)NC1=O
Drug Name: APROBARBITAL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CCC1(C(C)C)C(=O)NC(=O)NC1=O
Drug Name: APROBARBITAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)O[C@H]1C=COC=C2C[C@@]34SS[C@]5(CC6=COC=C[C@H](O)[C@H]6N5C3=O)C(=O)N4[C@@H]21
Candidate Name: ARANOTIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)O[C@H]1C=COC=C2C[C@@]34SS[C@]5(CC6=COC=C[C@H](O)[C@H]6N5C3=O)C(=O)N4[C@@H]21
Candidate Name: ARANOTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O",,"## Molecular Property Analysis: ADOZELESIN

### Structure
```
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 502.5 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 5.30 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 111.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.310
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ADOZELESIN

### Structure
```
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 502.5 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 5.30 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 111.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.310
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze the ADMET properties of this compound:
Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1",,"## Molecular Property Analysis: SULFAPYRIDINE

### Structure
```
Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 249.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.46 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 85.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.810
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: SULFAPYRIDINE

### Structure
```
Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 249.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.46 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 85.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.810
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
Drug Name: BENZGALANTAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
Drug Name: BENZGALANTAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1
Drug Name: CEFAZAFLUR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1
Drug Name: CEFAZAFLUR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2
Drug Name: ACETOPHENAZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2
Drug Name: ACETOPHENAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O
Name: EXIFONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 278.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 138.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O
Name: EXIFONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 278.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 138.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
OCCSCCO
Name: THIODIGLYCOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 122.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
OCCSCCO
Name: THIODIGLYCOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 122.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(CC(=O)O)Cc1nc2cc(Cl)cnc2n1Cc1ccc(Cl)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(CC(=O)O)Cc1nc2cc(Cl)cnc2n1Cc1ccc(Cl)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc(-n2c(-c3ccccc3)cc3c2CCc2ccccc2-3)ccc1O
FENDOSAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc(-n2c(-c3ccccc3)cc3c2CCc2ccccc2-3)ccc1O
FENDOSAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC1OC(=O)c2ccccc21
Drug Name: RAC-3-N-BUTYLPHTHALIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 190.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC1OC(=O)c2ccccc21
Drug Name: RAC-3-N-BUTYLPHTHALIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 190.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[Na+]
Name: CARBENICILLIN INDANYL SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[Na+]
Name: CARBENICILLIN INDANYL SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1
Drug Name: TARAFENACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1
Drug Name: TARAFENACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCOCCOC(=O)N1c2ccccc2Sc2ccccc21
DIMETHOXANATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCOCCOC(=O)N1c2ccccc2Sc2ccccc21
DIMETHOXANATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1
Name: GRAZOPREVIR ANHYDROUS",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 766.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1
Name: GRAZOPREVIR ANHYDROUS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 766.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
Candidate Name: DICLOFENSINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
Candidate Name: DICLOFENSINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CC(F)(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Candidate Name: CORMETHASONE ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CC(F)(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Candidate Name: CORMETHASONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl
Candidate Name: CYPROHEPTADINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl
Candidate Name: CYPROHEPTADINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCn1nc2c3c(c(NCCN)ccc31)Sc1cc(O)ccc1-2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCn1nc2c3c(c(NCCN)ccc31)Sc1cc(O)ccc1-2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COC1(OC)CCCN2CC(c3ccccc3)N=C21
OXAMISOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COC1(OC)CCCN2CC(c3ccccc3)N=C21
OXAMISOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[N+]1(Cc2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2
XENYTROPIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[N+]1(Cc2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2
XENYTROPIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC
Candidate Name: METHOXYVERAPAMIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC
Candidate Name: METHOXYVERAPAMIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
FOTEMUSTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
FOTEMUSTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
Drug Name: SORBITAN MONOOLEATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
Drug Name: SORBITAN MONOOLEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]
OXACILLIN SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]
OXACILLIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(C(Nc2ccc(S(N)(=O)=O)cc2)Nc2ccc(S(N)(=O)=O)cc2)ccc1O
Drug Name: VANYLDISULFAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(C(Nc2ccc(S(N)(=O)=O)cc2)Nc2ccc(S(N)(=O)=O)cc2)ccc1O
Drug Name: VANYLDISULFAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Nc1ccc(Cl)c(Cl)c1)NS(=O)(=O)c1ccc2c(c1)CCO2
Candidate Name: LY-295501",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Nc1ccc(Cl)c(Cl)c1)NS(=O)(=O)c1ccc2c(c1)CCO2
Candidate Name: LY-295501
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Name: MEMANTINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 215.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Name: MEMANTINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 215.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNc1ccc(C(=O)OCCN(C)C)cc1",,"## Molecular Property Analysis: TETRACAINE

### Structure
```
CCCCNc1ccc(C(=O)OCCN(C)C)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.62 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.580
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNc1ccc(C(=O)OCCN(C)C)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TETRACAINE

### Structure
```
CCCCNc1ccc(C(=O)OCCN(C)C)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.62 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.580
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)S[C@H]1CC(=O)C=C2C[C@@H](SC(C)=O)[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@]21C
Candidate Name: TIOMESTERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 450.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)S[C@H]1CC(=O)C=C2C[C@@H](SC(C)=O)[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@]21C
Candidate Name: TIOMESTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 450.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Compare the safety profiles of these two drugs:
Drug 1: NC(=O)OC[C@H](N)Cc1ccccc1 (SOLRIAMFETOL)
Drug 2: CC(C(C(=O)C(C)(C)C)c1ccc(Cl)cc1)N(C)C (Sibutramine)",,"## Comparative Drug Analysis

### Head-to-Head Comparison

| Property | SOLRIAMFETOL | Sibutramine | Better |
|----------|---------|---------|--------|
| Status | approved | withdrawn | üèÜ SOLRIAMFETOL |
| Mol. Weight | nan Da | nan Da | üèÜ Sibutramine |
| LogP | nan | nan | üèÜ Sibutramine |
| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Sibutramine |

### Assessment

**SOLRIAMFETOL** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.

**Sibutramine** has not achieved approval, which may indicate:
- Efficacy challenges in clinical trials
- Safety concerns that limited development
- Strategic decision to discontinue development",comparison,generated,"<|im_start|>user
Compare the safety profiles of these two drugs:
Drug 1: NC(=O)OC[C@H](N)Cc1ccccc1 (SOLRIAMFETOL)
Drug 2: CC(C(C(=O)C(C)(C)C)c1ccc(Cl)cc1)N(C)C (Sibutramine)
<|im_end|>
<|im_start|>assistant
## Comparative Drug Analysis

### Head-to-Head Comparison

| Property | SOLRIAMFETOL | Sibutramine | Better |
|----------|---------|---------|--------|
| Status | approved | withdrawn | üèÜ SOLRIAMFETOL |
| Mol. Weight | nan Da | nan Da | üèÜ Sibutramine |
| LogP | nan | nan | üèÜ Sibutramine |
| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Sibutramine |

### Assessment

**SOLRIAMFETOL** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.

**Sibutramine** has not achieved approval, which may indicate:
- Efficacy challenges in clinical trials
- Safety concerns that limited development
- Strategic decision to discontinue development
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1c(CC(=O)O)cccc1C(=O)c1ccccc1
AMFENAC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1c(CC(=O)O)cccc1C(=O)c1ccccc1
AMFENAC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+](C)(C)CCCCC[N+](C)(C)C
Candidate Name: PENTAMETHONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+](C)(C)CCCCC[N+](C)(C)C
Candidate Name: PENTAMETHONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1
Name: QUINETHAZONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1
Name: QUINETHAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
Candidate Name: BORTEZOMIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
Candidate Name: BORTEZOMIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl
Candidate Name: BETAXOLOL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 343.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl
Candidate Name: BETAXOLOL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 343.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N=C(NCCCc1c[nH]cn1)NCCNc1ccccn1
GAPROMIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N=C(NCCCc1c[nH]cn1)NCCNc1ccccn1
GAPROMIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(=O)c2c(O)c3ccoc3c(OCC(O)CNC(C)C)c2o1
Drug Name: IPROCROLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(=O)c2c(O)c3ccoc3c(OCC(O)CNC(C)C)c2o1
Drug Name: IPROCROLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(NCCCCCCc2ccccc2)nc(C)c1O
Name: ENAZADREM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(NCCCCCCc2ccccc2)nc(C)c1O
Name: ENAZADREM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Drug Name: ERYTHROMYCIN STEARATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1018.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Drug Name: ERYTHROMYCIN STEARATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1018.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cn1nc(-c2cccnc2)nc1-c1ccccc1CO
Name: FEPITRIZOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cn1nc(-c2cccnc2)nc1-c1ccccc1CO
Name: FEPITRIZOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1
Candidate Name: BITOLTEROL MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 557.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1
Candidate Name: BITOLTEROL MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 557.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
APREPITANT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 534.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
APREPITANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 534.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Candidate Name: DESOXIMETASONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Candidate Name: DESOXIMETASONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21
FLORBENAZINE F 18",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21
FLORBENAZINE F 18
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC
Candidate Name: WHI-P131",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC
Candidate Name: WHI-P131
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12
Name: PUERARIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 160.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12
Name: PUERARIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 160.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)CCc2ccccc2)CC1
Name: K-777",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)CCc2ccccc2)CC1
Name: K-777
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O",,"## Molecular Property Analysis: PENICILLIN V

### Structure
```
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 350.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PENICILLIN V

### Structure
```
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 350.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1
Drug Name: BROMINDIONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1
Drug Name: BROMINDIONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1
Candidate Name: ISPINESIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.59 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1
Candidate Name: ISPINESIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.59 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(C)(C)c1ccc(OCCCCCCN2CCN(c3ccc(C)c(Cl)c3)CC2)cc1
Candidate Name: TEROXALENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(C)(C)c1ccc(OCCCCCCN2CCN(c3ccc(C)c(Cl)c3)CC2)cc1
Candidate Name: TEROXALENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)CCCN.Cl
Candidate Name: BL-1021",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)CCCN.Cl
Candidate Name: BL-1021
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
Name: PHENYTOIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
Name: PHENYTOIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1CC[C@H]2[C@H]3Cc4cccc(O)c4[C@@]2(CCN3CC2CC2)C1
Name: KETORFANOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1CC[C@H]2[C@H]3Cc4cccc(O)c4[C@@]2(CCN3CC2CC2)C1
Name: KETORFANOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
Nc1c2c(nc3ccccc13)CCCC2",,"## Molecular Property Analysis: TACRINE

### Structure
```
Nc1c2c(nc3ccccc13)CCCC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 198.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 38.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Nc1c2c(nc3ccccc13)CCCC2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TACRINE

### Structure
```
Nc1c2c(nc3ccccc13)CCCC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 198.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 38.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)Cn1cc(I)c(=O)c(I)c1
DIODONE ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)Cn1cc(I)c(=O)c(I)c1
DIODONE ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1c1ccc(=O)oc1
Candidate Name: CINOBUFOTALIN",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1c1ccc(=O)oc1
Candidate Name: CINOBUFOTALIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
[Ca+2].[N-]=C=[N-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 80.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
[Ca+2].[N-]=C=[N-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 80.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCCC(C)(O)/C=C/C1CCC(=O)[C@@H]1CCCCCCC(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 352.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCCC(C)(O)/C=C/C1CCC(=O)[C@@H]1CCCCCCC(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 352.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 379.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 379.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]",,"## Molecular Property Analysis: L-NAME

### Structure
```
COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 233.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.43 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 143.4 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: L-NAME

### Structure
```
COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 233.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.43 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 143.4 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCOc1ccccc1O/C(=C/c1ccccc1)C(C)=O
Name: ZOCAINONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCOc1ccccc1O/C(=C/c1ccccc1)C(C)=O
Name: ZOCAINONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1C[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O
Candidate Name: MELENGESTROL ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1C[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O
Candidate Name: MELENGESTROL ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Drug Name: BUTYLSCOPOLAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Drug Name: BUTYLSCOPOLAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1c(Cl)cc(CC2=NCCN2)cc1Cl
Drug Name: NEMAZOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1c(Cl)cc(CC2=NCCN2)cc1Cl
Drug Name: NEMAZOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cn1c(=O)c2c(ncn2CCCN[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3O[N+](=O)[O-])n(C)c1=O
Name: TEOPRANITOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 144.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cn1c(=O)c2c(ncn2CCCN[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3O[N+](=O)[O-])n(C)c1=O
Name: TEOPRANITOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 144.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cccc(C)c1NC(=O)c1ccc(N)cc1
AMELTOLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cccc(C)c1NC(=O)c1ccc(N)cc1
AMELTOLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)N=C(N)N=C(N)N1OCc1ccc(Cl)c(Cl)c1
CLOCIGUANIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)N=C(N)N=C(N)N1OCc1ccc(Cl)c(Cl)c1
CLOCIGUANIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOP(=O)(NC(=S)Nc1ccccc1NC(=O)NS(=O)(=O)c1ccc(C)cc1)OCC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 500.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOP(=O)(NC(=S)Nc1ccccc1NC(=O)NS(=O)(=O)c1ccc(C)cc1)OCC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 500.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCc1cccc(CO)n1
Name: PIRIFIBRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCc1cccc(CO)n1
Name: PIRIFIBRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C#N)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Candidate Name: CICORTONIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 566.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C#N)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Candidate Name: CICORTONIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 566.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
NALTREXONE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
NALTREXONE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1
Candidate Name: GW590735",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1
Candidate Name: GW590735
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NS(=O)(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Name: SUNCILLIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NS(=O)(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Name: SUNCILLIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Candidate Name: FLUPREDNIDENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Candidate Name: FLUPREDNIDENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1Oc2ccccc2CC1N(C)C
TREBENZOMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1Oc2ccccc2CC1N(C)C
TREBENZOMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1
Name: SUTEZOLID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1
Name: SUTEZOLID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1
Candidate Name: TELOTRISTAT ETHYL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 575.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1
Candidate Name: TELOTRISTAT ETHYL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 575.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
Drug Name: DEXTROMETHORPHAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
Drug Name: DEXTROMETHORPHAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
NNC(=O)c1ccncc1",,"## Molecular Property Analysis: ISONIAZID

### Structure
```
NNC(=O)c1ccncc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 137.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.31 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 68.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
NNC(=O)c1ccncc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ISONIAZID

### Structure
```
NNC(=O)c1ccncc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 137.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.31 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 68.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCCCCCC(O)c1ccc(C(=O)O)c(Cl)c1
Name: LODELABEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.33 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCCCCCC(O)c1ccc(C(=O)O)c(Cl)c1
Name: LODELABEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.33 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(c1cc2ccccc2s1)N(O)C(N)=O
Candidate Name: ZILEUTON",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(c1cc2ccccc2s1)N(O)C(N)=O
Candidate Name: ZILEUTON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1
Candidate Name: HALAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1
Candidate Name: HALAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
Name: FOSINOPRIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 563.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
Name: FOSINOPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 563.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cn1c(=O)c2c(ncn2CC(O)CN2CCN(CCCSc3ccccc3)CC2)n(C)c1=O
Name: TAZIFYLLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cn1c(=O)c2c(ncn2CC(O)CN2CCN(CCCSc3ccccc3)CC2)n(C)c1=O
Name: TAZIFYLLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
MARIMASTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
MARIMASTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=P1(N(CCCl)CCCl)NC(SCCS(=O)(=O)O)CCO1
Name: MAFOSFAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=P1(N(CCCl)CCCl)NC(SCCS(=O)(=O)O)CCO1
Name: MAFOSFAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 501.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 501.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C
Candidate Name: EUCATROPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C
Candidate Name: EUCATROPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21
Name: IZORLISIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21
Name: IZORLISIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC12CC3CC(C)(C1)CC(N)(C3)C2
MEMANTINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC12CC3CC(C)(C1)CC(N)(C3)C2
MEMANTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl
CONIVAPTAN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 535.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl
CONIVAPTAN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 535.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
Name: TERAZOSIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
Name: TERAZOSIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
Drug Name: CAMPTOTHECIN-20-O-PROPIONATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
Drug Name: CAMPTOTHECIN-20-O-PROPIONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
Name: TYLOSIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 916.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 238.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
Name: TYLOSIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 916.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 238.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1C(C)(C)CCCC1(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 155.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1C(C)(C)CCCC1(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 155.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1CCCC1=O",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 99.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1CCCC1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 99.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1
Drug Name: AT-13148",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1
Drug Name: AT-13148
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(C2(c3ccccc3)NC(=O)N(CCCN3CCC(c4ccccc4)CC3)C2=O)cc1
Name: ROPITOIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 483.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(C2(c3ccccc3)NC(=O)N(CCCN3CCC(c4ccccc4)CC3)C2=O)cc1
Name: ROPITOIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 483.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOP(=O)(CCCCCCOc1ccc(OC)cc1Cl)OCC
FOSARILATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOP(=O)(CCCCCCOc1ccc(OC)cc1Cl)OCC
FOSARILATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN1C(=CC=CC=Cc2sc3ccccc3[n+]2CC)Sc2ccccc21
Drug Name: DITHIAZANINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN1C(=CC=CC=Cc2sc3ccccc3[n+]2CC)Sc2ccccc21
Drug Name: DITHIAZANINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2",,"## Molecular Property Analysis: BERMOPROFEN

### Structure
```
Cc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 296.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.920
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BERMOPROFEN

### Structure
```
Cc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 296.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.920
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Drug Name: SCOPOLAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Drug Name: SCOPOLAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl",,"## Molecular Property Analysis: TICRYNAFEN

### Structure
```
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 331.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TICRYNAFEN

### Structure
```
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 331.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
SARACATINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 542.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
SARACATINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 542.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1",,"## Molecular Property Analysis: CLOZAPINE

### Structure
```
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 326.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CLOZAPINE

### Structure
```
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 326.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN1C(=CC=Cc2ccc3ccccc3[n+]2CC)C=Cc2ccccc21
QUINALDINE BLUE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.60 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN1C(=CC=Cc2ccc3ccccc3[n+]2CC)C=Cc2ccccc21
QUINALDINE BLUE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.60 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1
Name: MOZENAVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1
Name: MOZENAVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]c2ccccc2n1C1CCN(CCCc2noc3cc(F)ccc23)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]c2ccccc2n1C1CCN(CCCc2noc3cc(F)ccc23)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
OC(c1ccccc1)C1CCN(CCc2ccccc2)CC1
GLEMANSERIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
OC(c1ccccc1)C1CCN(CCc2ccccc2)CC1
GLEMANSERIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O
Candidate Name: PIFLUFOLASTAT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O
Candidate Name: PIFLUFOLASTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)C1N=C(c2ccccc2F)c2cc(Cl)ccc2NC1=O
Name: ETHYL LOFLAZEPATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)C1N=C(c2ccccc2F)c2cc(Cl)ccc2NC1=O
Name: ETHYL LOFLAZEPATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O
Name: TOBRAMYCIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -6.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 268.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O
Name: TOBRAMYCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -6.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 268.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23
FLUMEQUINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 261.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23
FLUMEQUINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 261.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Candidate Name: ORANTINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Candidate Name: ORANTINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
OCCOCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1
Name: PIPOXIZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
OCCOCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1
Name: PIPOXIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)N1c2ccccc2CC(=O)c2ccccc21
Drug Name: OXCARBAZEPINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)N1c2ccccc2CC(=O)c2ccccc21
Drug Name: OXCARBAZEPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCn1nnc(C2=CCCN(C)C2)n1
Name: ALVAMELINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCn1nnc(C2=CCCN(C)C2)n1
Name: ALVAMELINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C#CC(C)(O)CC
Candidate Name: MEPARFYNOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 98.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C#CC(C)(O)CC
Candidate Name: MEPARFYNOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 98.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
ISOSORBIDE MONONITRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
ISOSORBIDE MONONITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1csc2ccc3[nH]c4c(c3c12)CN(C)CC4
TIENOCARBINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1csc2ccc3[nH]c4c(c3c12)CN(C)CC4
TIENOCARBINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O
Candidate Name: CARBIDOPA",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O
Candidate Name: CARBIDOPA
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
SACUBITRIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
SACUBITRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1
Drug Name: TEMANOGREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1
Drug Name: TEMANOGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2CCCc2ccc(C(=O)O)s2)cc1
Name: AGANEPAG",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2CCCc2ccc(C(=O)O)s2)cc1
Name: AGANEPAG
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 429.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O
CORDYCEPIN",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O
CORDYCEPIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C",,"## Molecular Property Analysis: DISOPYRAMIDE

### Structure
```
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 339.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.36 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 59.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DISOPYRAMIDE

### Structure
```
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 339.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.36 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 59.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCC
Candidate Name: BUTANE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 58.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCC
Candidate Name: BUTANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 58.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCn1ccnc1CC1COc2ccccc2O1
IMILOXAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCn1ccnc1CC1COc2ccccc2O1
IMILOXAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NCCCC(=O)O
Drug Name: GAMMA-AMINOBUTYRIC ACID",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 103.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NCCCC(=O)O
Drug Name: GAMMA-AMINOBUTYRIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 103.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@@H](COC(=O)c1cc(OC)c(OC)c(OC)c1)N(C)CCN(C)[C@@H](CC)COC(=O)c1cc(OC)c(OC)c(OC)c1
Name: BUTOBENDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 620.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@@H](COC(=O)c1cc(OC)c(OC)c(OC)c1)N(C)CCN(C)[C@@H](CC)COC(=O)c1cc(OC)c(OC)c(OC)c1
Name: BUTOBENDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 620.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Name: PHTHALYLSULFATHIAZOLE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 403.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Name: PHTHALYLSULFATHIAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 403.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOc1ccc(S(=O)(=O)O)c2cccnc12
Drug Name: ACTINOQUINOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOc1ccc(S(=O)(=O)O)c2cccnc12
Drug Name: ACTINOQUINOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CCN(C)CCCN2Cc3cc(OC)c(OC)cc3C2=O)cc1OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CCN(C)CCCN2Cc3cc(OC)c(OC)cc3C2=O)cc1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN1CCC(=C(c2ccccc2)c2ccccc2)C1
Name: PRIDEFINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN1CCC(=C(c2ccccc2)c2ccccc2)C1
Name: PRIDEFINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21
Candidate Name: TRANDOLAPRIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21
Candidate Name: TRANDOLAPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C
Name: PYROTINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 583.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C
Name: PYROTINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 583.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C([O-])CCCCCCCNC(=O)c1ccccc1O.[Na+]
Candidate Name: SALCAPROZATE SODIUM",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C([O-])CCCCCCCNC(=O)c1ccccc1O.[Na+]
Candidate Name: SALCAPROZATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)Oc1ccc(C(c2ccc(OP(=O)(O)O)cc2)c2ccccn2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)Oc1ccc(C(c2ccc(OP(=O)(O)O)cc2)c2ccccn2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Drug Name: ISOFLUPREDONE ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Drug Name: ISOFLUPREDONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1
Name: MIRISTALKONIUM ION",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.96 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1
Name: MIRISTALKONIUM ION
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.96 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1
Candidate Name: PIPERIDOLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1
Candidate Name: PIPERIDOLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Candidate Name: OXANDROLONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Candidate Name: OXANDROLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC(=O)C(c1ccccc1)C1CCCCN1
Name: METHYLPHENIDATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC(=O)C(c1ccccc1)C1CCCCN1
Name: METHYLPHENIDATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1
Name: TEPIRINDOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1
Name: TEPIRINDOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
Candidate Name: RIMEGEPANT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 534.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
Candidate Name: RIMEGEPANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 534.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O
ADOZELESIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 502.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O
ADOZELESIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 502.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1
Name: PF-5190457",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1
Name: PF-5190457
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
DAPRODUSTAT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
DAPRODUSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1C(I)=CC(=C(c2cc(I)c([O-])c(I)c2)c2ccccc2C(=O)[O-])C=C1I.[Na+].[Na+]
Drug Name: IODOPHTHALEIN SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 865.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.32 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1C(I)=CC(=C(c2cc(I)c([O-])c(I)c2)c2ccccc2C(=O)[O-])C=C1I.[Na+].[Na+]
Drug Name: IODOPHTHALEIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 865.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.32 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1",,"## Molecular Property Analysis: HYDROXYFLUTAMIDE

### Structure
```
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 292.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.32 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 92.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: HYDROXYFLUTAMIDE

### Structure
```
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 292.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.32 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 92.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)C1=Cc2cc(OC(F)(F)F)ccc2OC1C(F)(F)F",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 328.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)C1=Cc2cc(OC(F)(F)F)ccc2OC1C(F)(F)F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 328.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1cccc(Nc2ccccc2C(=O)O)c1C",,"## Molecular Property Analysis: MEFENAMIC ACID

### Structure
```
Cc1cccc(Nc2ccccc2C(=O)O)c1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 241.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1cccc(Nc2ccccc2C(=O)O)c1C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MEFENAMIC ACID

### Structure
```
Cc1cccc(Nc2ccccc2C(=O)O)c1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 241.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 444.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 444.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Drug Name: TELAPRISTONE ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 505.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Drug Name: TELAPRISTONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 505.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1C[C@H](CC#N)C[C@@H]2c3cccc4[nH]c(Cl)c(c34)C[C@H]21
Name: LERGOTRILE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1C[C@H](CC#N)C[C@@H]2c3cccc4[nH]c(Cl)c(c34)C[C@H]21
Name: LERGOTRILE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
Name: CHLORPROTHIXENE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.19 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
Name: CHLORPROTHIXENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.19 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Fc1ccc(-c2ccc(CN3CCN(c4cccc5ccoc45)CC3)[nH]2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Fc1ccc(-c2ccc(CN3CCN(c4cccc5ccoc45)CC3)[nH]2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1411.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1411.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NCCc1cc[nH]n1
Candidate Name: BETAZOLE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NCCc1cc[nH]n1
Candidate Name: BETAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc2ccc(=O)oc2cc1OCCCN1CCC(C(O)(c2ccc(F)cc2)c2ccc(F)cc2)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 535.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc2ccc(=O)oc2cc1OCCCN1CCC(C(O)(c2ccc(F)cc2)c2ccc(F)cc2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 535.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=O
Drug Name: OXYGEN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 32.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=O
Drug Name: OXYGEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 32.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1C2Cc3ccccc3C1(C)CCN2CC1CC1
VOLAZOCINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1C2Cc3ccccc3C1(C)CCN2CC1CC1
VOLAZOCINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C([O-])O.[K+]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 100.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C([O-])O.[K+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 100.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC1CCC(NC(=O)N(CCCl)N=O)CC1",,"## Molecular Property Analysis: SEMUSTINE

### Structure
```
CC1CCC(NC(=O)N(CCCl)N=O)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 247.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.50 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC1CCC(NC(=O)N(CCCl)N=O)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: SEMUSTINE

### Structure
```
CC1CCC(NC(=O)N(CCCl)N=O)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 247.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.50 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(N)CCCC(C)(C)O
Candidate Name: HEPTAMINOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 145.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(N)CCCC(C)(C)O
Candidate Name: HEPTAMINOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 145.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)C(C)=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 116.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)C(C)=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 116.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1CC(OC(=O)C(C)O)CC(C)(C)C1
CICLACTATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1CC(OC(=O)C(C)O)CC(C)(C)C1
CICLACTATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1
Candidate Name: AZD2066",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1
Candidate Name: AZD2066
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCC1(CCCCC)Cc2c(cc(C(C)(C)C)c(O)c2C(C)(C)C)O1
Drug Name: BO-653",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.82 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCC1(CCCCC)Cc2c(cc(C(C)(C)C)c(O)c2C(C)(C)C)O1
Drug Name: BO-653
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.82 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
Candidate Name: NIMODIPINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
Candidate Name: NIMODIPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(=O)c1nnc(C(C)(C)C)o1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(=O)c1nnc(C(C)(C)C)o1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
c1ccc(C(CCN2CCCCCC2)c2ccccc2)cc1
Name: PROZAPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
c1ccc(C(CCN2CCCCCC2)c2ccccc2)cc1
Name: PROZAPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(CC)C1(CC)C(=O)NC(=O)NC1=O
Drug Name: TETRABARBITAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(CC)C1(CC)C(=O)NC(=O)NC1=O
Drug Name: TETRABARBITAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(CCC)C(N)=O
Drug Name: VALPROMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 143.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(CCC)C(N)=O
Drug Name: VALPROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 143.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2
Drug Name: SETROBUVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 560.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2
Drug Name: SETROBUVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 560.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)CC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1
Name: BUTHIAZIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)CC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1
Name: BUTHIAZIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
c1ccc2c(c1)CCCC2C1=NCCN1
TETRAHYDROZOLINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
c1ccc2c(c1)CCCC2C1=NCCN1
TETRAHYDROZOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
NITROGLYCERIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 157.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
NITROGLYCERIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 157.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1cc(-c2ccccc2)n(-c2ccccc2)n1CCCN1CCN(c2ccccn2)CC1
Drug Name: REVENAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1cc(-c2ccccc2)n(-c2ccccc2)n1CCCN1CCN(c2ccccn2)CC1
Drug Name: REVENAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)=CCN1Cc2c(Cl)ccc3[nH]c(=S)n(c23)C[C@@H]1C
TIVIRAPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)=CCN1Cc2c(Cl)ccc3[nH]c(=S)n(c23)C[C@@H]1C
TIVIRAPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2
ZENIDOLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2
ZENIDOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1
Drug Name: CEFTOBIPROLE MEDOCARIL FREE ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 690.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 264.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1
Drug Name: CEFTOBIPROLE MEDOCARIL FREE ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 690.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 264.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)C(COC(=O)c1ccc(N)cc1)CC(C)C
LEUCINOCAINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)C(COC(=O)c1ccc(N)cc1)CC(C)C
LEUCINOCAINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1
Drug Name: NANATINOSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1
Drug Name: NANATINOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Name: FLURITHROMYCIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 751.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Name: FLURITHROMYCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 751.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)C(Cc1ccccn1)P(=O)(O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)C(Cc1ccccn1)P(=O)(O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOP(=S)(OCC)Oc1cc(C)nc(N(C)C)n1
Name: PYRIMITATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOP(=S)(OCC)Oc1cc(C)nc(N(C)C)n1
Name: PYRIMITATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1.CS(=O)(=O)O",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 793.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1.CS(=O)(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 793.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Drug Name: TENAPANOR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1145.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Drug Name: TENAPANOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1145.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 155.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 155.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1
GSK-729327",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1
GSK-729327
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(C(=O)NCCc2c[nH]c3ccccc23)cc1
Name: Compound_EXP004",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(C(=O)NCCc2c[nH]c3ccccc23)cc1
Name: Compound_EXP004
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(=O)Nc1nnc(S(N)(=O)=O)s1",,"## Molecular Property Analysis: ACETAZOLAMIDE

### Structure
```
CC(=O)Nc1nnc(S(N)(=O)=O)s1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.86 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 115.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(=O)Nc1nnc(S(N)(=O)=O)s1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ACETAZOLAMIDE

### Structure
```
CC(=O)Nc1nnc(S(N)(=O)=O)s1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.86 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 115.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1
Candidate Name: PF-04995274",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1
Candidate Name: PF-04995274
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
CRENOLANIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
CRENOLANIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)CCO[N+](=O)[O-].[O-][Cl+3]([O-])([O-])[O-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)CCO[N+](=O)[O-].[O-][Cl+3]([O-])([O-])[O-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1
RIZATRIPTAN BENZOATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1
RIZATRIPTAN BENZOATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1
Name: ST1535",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1
Name: ST1535
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1oc2ccccc2c1CC(C)(C)COc1ccc(CC2SC(=O)NC2=O)cc1
Drug Name: Troglitazone",,"## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1oc2ccccc2c1CC(C)(C)COc1ccc(CC2SC(=O)NC2=O)cc1
Drug Name: Troglitazone
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(c1ccccc1)C1CCCC1)C2
Candidate Name: CICLOTROPIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(c1ccccc1)C1CCCC1)C2
Candidate Name: CICLOTROPIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(Cl)c(C)cc1c2CN1CCC(C)CC1
Candidate Name: ELOMOTECAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 522.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(Cl)c(C)cc1c2CN1CCC(C)CC1
Candidate Name: ELOMOTECAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 522.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)COC(=O)CCC(=O)[O-])CC[C@@H]12.[Na+]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)COC(=O)CCC(=O)[O-])CC[C@@H]12.[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1ncc([N+](=O)[O-])n1CCO.Cl
Name: METRONIDAZOLE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 207.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1ncc([N+](=O)[O-])n1CCO.Cl
Name: METRONIDAZOLE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 207.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1
Name: IPSAPIRONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1
Name: IPSAPIRONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2
Candidate Name: ETHYBENZTROPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2
Candidate Name: ETHYBENZTROPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
OCCNCCO
Name: DIETHANOLAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 105.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
OCCNCCO
Name: DIETHANOLAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 105.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1CCN2c3ccccc3Cc3ccccc3C2C1",,"## Molecular Property Analysis: MIANSERIN

### Structure
```
CN1CCN2c3ccccc3Cc3ccccc3C2C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.08 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1CCN2c3ccccc3Cc3ccccc3C2C1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MIANSERIN

### Structure
```
CN1CCN2c3ccccc3Cc3ccccc3C2C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.08 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1
RACEMORAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1
RACEMORAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1
Name: CYCLOHEXIMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1
Name: CYCLOHEXIMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1
Name: LERSIVIRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1
Name: LERSIVIRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+]
SULBACTAM SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+]
SULBACTAM SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Drug Name: RIBAVIRIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Drug Name: RIBAVIRIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1c(C)c2ccc(OCCCN3CCN(Cc4ccc(Cl)cc4)CC3)cc2oc1=O
PICUMAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1c(C)c2ccc(OCCCN3CCN(Cc4ccc(Cl)cc4)CC3)cc2oc1=O
PICUMAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3
Candidate Name: Valdecoxib (Bextra)",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3
Candidate Name: Valdecoxib (Bextra)
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1c2ccccc2C(=O)C1c1ccc(C(F)(F)F)cc1
Candidate Name: FLUINDAROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1c2ccccc2C(=O)C1c1ccc(C(F)(F)F)cc1
Candidate Name: FLUINDAROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
FLECAINIDE ACETATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
FLECAINIDE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1)C(=O)O
Candidate Name: CMX-2043",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1)C(=O)O
Candidate Name: CMX-2043
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Name: PRASTERONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Name: PRASTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 634.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 634.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NCCc1c[nH]cn1
Name: HISTAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NCCc1c[nH]cn1
Name: HISTAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)c1ccc(C(F)(F)F)cc1OP(=O)(O)O
FLUFOSAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)c1ccc(C(F)(F)F)cc1OP(=O)(O)O
FLUFOSAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1
L-21649",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1
L-21649
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1
PROPENZOLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1
PROPENZOLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO",,"## Molecular Property Analysis: PREDNISONE

### Structure
```
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.780
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PREDNISONE

### Structure
```
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.780
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1
Candidate Name: IMIGLITAZAR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.01 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1
Candidate Name: IMIGLITAZAR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.01 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O
Name: OSILODROSTAT PHOSPHATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O
Name: OSILODROSTAT PHOSPHATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)[O-].CC(=O)[O-].[Ca+2]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 158.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)[O-].CC(=O)[O-].[Ca+2]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 158.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1(C)CN2C(=O)c3[nH]cnc3N(Cc3ccc(Cl)cc3)C2=N1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1(C)CN2C(=O)c3[nH]cnc3N(Cc3ccc(Cl)cc3)C2=N1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)Nc1c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c(I)c(N(C)C(C)=O)c1I
Name: METRIZAMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 789.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 168.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)Nc1c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c(I)c(N(C)C(C)=O)c1I
Name: METRIZAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 789.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 168.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(C)C(C)C(O)c1ccccc1
Candidate Name: ETAFEDRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(C)C(C)C(O)c1ccccc1
Candidate Name: ETAFEDRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(SC(=O)c1cccs1)C(=O)NCC(=O)O
Drug Name: STEPRONIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(SC(=O)c1cccs1)C(=O)NCC(=O)O
Drug Name: STEPRONIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl
Name: BUCLIZINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.54 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl
Name: BUCLIZINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.54 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21",,"## Molecular Property Analysis: CLAVULANIC ACID

### Structure
```
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 199.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.10 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 87.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CLAVULANIC ACID

### Structure
```
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 199.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.10 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 87.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)CCCC(C)N",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 129.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)CCCC(C)N
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 129.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
Candidate Name: TADALAFIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
Candidate Name: TADALAFIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O",,"## Molecular Property Analysis: TAZOBACTAM

### Structure
```
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 300.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.52 | 0-5 | ‚ö† |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 122.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TAZOBACTAM

### Structure
```
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 300.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.52 | 0-5 | ‚ö† |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 122.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC(=O)OC1CCN(CCCC(=O)c2ccc(F)cc2)C2CCCCC12
Name: CICARPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC(=O)OC1CCN(CCCC(=O)c2ccc(F)cc2)C2CCCCC12
Name: CICARPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ncc(/C(=N/OC2CCNC2=O)C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(C[n+]4ccccc4)CS[C@H]23)s1
CEFEMPIDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 543.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 183.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ncc(/C(=N/OC2CCNC2=O)C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(C[n+]4ccccc4)CS[C@H]23)s1
CEFEMPIDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 543.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 183.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(C(O)CCC2CCNCC2)c2ccccc2n1
Drug Name: QUINACAINOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(C(O)CCC2CCNCC2)c2ccccc2n1
Drug Name: QUINACAINOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(c1ccccc1Nc1ccncc1)N1CCCCC1
Name: OFORNINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(c1ccccc1Nc1ccncc1)N1CCCCC1
Name: OFORNINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Drug Name: SEVOFLURANE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Drug Name: SEVOFLURANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
CORTISONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
CORTISONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
GENISTEIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
GENISTEIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(=O)/C(Br)=C\C(=O)O)cc1
Candidate Name: BROMEBRIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(=O)/C(Br)=C\C(=O)O)cc1
Candidate Name: BROMEBRIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Candidate Name: NETUPITANT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 578.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.79 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Candidate Name: NETUPITANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 578.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.79 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1cccnc1
NIOMETACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1cccnc1
NIOMETACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(O)CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)O)cc2)cc1
Candidate Name: SULFOXONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(O)CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)O)cc2)cc1
Candidate Name: SULFOXONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn([11CH3])c2Sc2ccc(Cl)cn2)cc1
Candidate Name: MK-3168 C-11",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn([11CH3])c2Sc2ccc(Cl)cn2)cc1
Candidate Name: MK-3168 C-11
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)N[C@@H](CSC(C)=O)C(=O)O
DACISTEINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 205.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)N[C@@H](CSC(C)=O)C(=O)O
DACISTEINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 205.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1
Name: BGC-20-1531 FREE BASE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 492.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1
Name: BGC-20-1531 FREE BASE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 492.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCc1c(OCCCCCOc2cc3c(cc2C(C)=O)CCC(C(=O)O)O3)ccc(C(C)=O)c1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCc1c(OCCCCCOc2cc3c(cc2C(C)=O)CCC(C(=O)O)O3)ccc(C(C)=O)c1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O",,"## Molecular Property Analysis: CILASTATIN

### Structure
```
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.43 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 129.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CILASTATIN

### Structure
```
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.43 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 129.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O
Name: FENOFIBRIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O
Name: FENOFIBRIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cl.NCCCC(N)(C(=O)O)C(F)F.O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cl.NCCCC(N)(C(=O)O)C(F)F.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
[F-].[Na+]
SODIUM FLUORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 42.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
[F-].[Na+]
SODIUM FLUORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 42.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)NC(CCC(=O)O)C(=O)O
ACEGLUMATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)NC(CCC(=O)O)C(=O)O
ACEGLUMATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C
Name: BREMAZOCINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C
Name: BREMAZOCINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N=C1C=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=C1
PARAROSANILINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N=C1C=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=C1
PARAROSANILINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)c1cccnc1Nc1cccc(Cl)c1Cl
Drug Name: DICLONIXIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 283.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)c1cccnc1Nc1cccc(Cl)c1Cl
Drug Name: DICLONIXIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 283.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC(=O)CCC/C=C\C[C@@H]1[C@@H](C#C[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O
Name: ALFAPROSTOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC(=O)CCC/C=C\C[C@@H]1[C@@H](C#C[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O
Name: ALFAPROSTOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1
Name: CEFPIROME",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1
Name: CEFPIROME
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[S+](C)CCOC(=O)C(c1ccccc1)C1CCCCC1
Drug Name: HEXASONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[S+](C)CCOC(=O)C(c1ccccc1)C1CCCCC1
Drug Name: HEXASONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 427.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 148.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 427.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 148.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1",,"## Molecular Property Analysis: DIFLOXACIN

### Structure
```
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 399.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 65.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.730
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DIFLOXACIN

### Structure
```
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 399.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 65.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.730
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Drug Name: TOLMETIN SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Drug Name: TOLMETIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)CCOC(Cc1ccccc1)c1ccccc1.[Br-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)CCOC(Cc1ccccc1)c1ccccc1.[Br-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1CN1CCN(CCOC(c2ccccc2)c2ccccc2Cl)CC1
CHLORBENZOXAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 435.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1CN1CCN(CCOC(c2ccccc2)c2ccccc2Cl)CC1
CHLORBENZOXAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 435.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12
Name: DALFOPRISTIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 690.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 176.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12
Name: DALFOPRISTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 690.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 176.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)O[C@@]1(c2ccccc2)CCN(C)C[C@@H]1C
Candidate Name: BETAPRODINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 261.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)O[C@@]1(c2ccccc2)CCN(C)C[C@@H]1C
Candidate Name: BETAPRODINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 261.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1",,"## Molecular Property Analysis: MAVACOXIB

### Structure
```
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 385.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.34 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 78.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MAVACOXIB

### Structure
```
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 385.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.34 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 78.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)c1nc2c3cc(C)ccc3n(CC)c(=O)n2n1
Candidate Name: MELQUINAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)c1nc2c3cc(C)ccc3n(CC)c(=O)n2n1
Candidate Name: MELQUINAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1
TEGOBUVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1
TEGOBUVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COCCOC(=O)NS(=O)(=O)c1ccc(C)cc1
TOSULUR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COCCOC(=O)NS(=O)(=O)c1ccc(C)cc1
TOSULUR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12
UMIFENOVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12
UMIFENOVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21",,"## Molecular Property Analysis: DIAZEPAM

### Structure
```
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.15 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 32.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DIAZEPAM

### Structure
```
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.15 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 32.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(NCCCCc1ccccc1)C(O)c1ccc2c(c1)CCS2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(NCCCCc1ccccc1)C(O)c1ccc2c(c1)CCS2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC(C)(COC(N)=O)COC(=O)NC1CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC(C)(COC(N)=O)COC(=O)NC1CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1",,"## Molecular Property Analysis: ZD-4190 FREE BASE

### Structure
```
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 459.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.95 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 87.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ZD-4190 FREE BASE

### Structure
```
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 459.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.95 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 87.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
c1ccc(-c2nn(-c3ccccc3)[n+](-c3ccc(-c4ccc(-[n+]5nc(-c6ccccc6)nn5-c5ccccc5)cc4)cc3)n2)cc1
NEOTETRAZOLIUM",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 596.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
c1ccc(-c2nn(-c3ccccc3)[n+](-c3ccc(-c4ccc(-[n+]5nc(-c6ccccc6)nn5-c5ccccc5)cc4)cc3)n2)cc1
NEOTETRAZOLIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 596.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1",,"## Molecular Property Analysis: TERFENADINE

### Structure
```
CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 471.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 43.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.400
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TERFENADINE

### Structure
```
CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 471.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 43.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.400
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(C)c1C(OCCOCCN(C)C)c1c(C)cccc1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(C)c1C(OCCOCCN(C)C)c1c(C)cccc1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCCN(C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCCN(C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)/C=C/c1ccc(O)c(O)c1",,"## Molecular Property Analysis: CAFFEIC ACID

### Structure
```
O=C(O)/C=C/c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 180.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.20 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)/C=C/c1ccc(O)c(O)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CAFFEIC ACID

### Structure
```
O=C(O)/C=C/c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 180.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.20 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)OCCCNCCC(c2ccccc2)c2ccccc2)cc(OC)c1OC
Name: MEPRAMIDIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 463.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)OCCCNCCC(c2ccccc2)c2ccccc2)cc(OC)c1OC
Name: MEPRAMIDIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 463.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCOc1ccc(/C(=C(\Cl)c2ccccc2)c2ccccc2)cc1
Drug Name: ZUCLOMIPHENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCOc1ccc(/C(=C(\Cl)c2ccccc2)c2ccccc2)cc1
Drug Name: ZUCLOMIPHENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NCC(O)COc1ccccc1NC(=O)c1ccco1
Name: ANCAROLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NCC(O)COc1ccccc1NC(=O)c1ccco1
Name: ANCAROLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 250.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 250.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.Cl.Cl
Name: CHLOROQUINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.Cl.Cl
Name: CHLOROQUINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COC(=O)c1nc2cc(Cl)c3cccnc3c2o1",,"## Molecular Property Analysis: QUAZOLAST

### Structure
```
COC(=O)c1nc2cc(Cl)c3cccnc3c2o1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 262.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.82 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COC(=O)c1nc2cc(Cl)c3cccnc3c2o1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: QUAZOLAST

### Structure
```
COC(=O)c1nc2cc(Cl)c3cccnc3c2o1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 262.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.82 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
Name: NITRAZEPAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
Name: NITRAZEPAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O
Name: SELODENOSON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O
Name: SELODENOSON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)=CCOc1cc(NC(=S)c2ccoc2C)ccc1Cl
Drug Name: UC 781",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.37 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)=CCOc1cc(NC(=S)c2ccoc2C)ccc1Cl
Drug Name: UC 781
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.37 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC",,"## Molecular Property Analysis: TRIMETREXATE

### Structure
```
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 369.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 117.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TRIMETREXATE

### Structure
```
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 369.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 117.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CC(C(=O)O)C(P(=O)(O)O)P(=O)(O)O
Drug Name: BUTEDRONIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 189.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CC(C(=O)O)C(P(=O)(O)O)P(=O)(O)O
Drug Name: BUTEDRONIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 189.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COC(=O)C(c1ccccc1)C1CCCCN1.Cl
METHYLPHENIDATE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COC(=O)C(c1ccccc1)C1CCCCN1.Cl
METHYLPHENIDATE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Drug Name: Levothyroxine",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Drug Name: Levothyroxine
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C
ESTRADIOL VALERATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C
ESTRADIOL VALERATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O
Candidate Name: TIPELUKAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 530.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O
Candidate Name: TIPELUKAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 530.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(OOC(=O)c1ccccc1)c1ccccc1
BENZOYL PEROXIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(OOC(=O)c1ccccc1)c1ccccc1
BENZOYL PEROXIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12
SAR-407899",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12
SAR-407899
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)COc1ccc(CCNC(=O)NC(C)C)cc1
PAFENOLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)COc1ccc(CCNC(=O)NC(C)C)cc1
PAFENOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O
CILAZAPRILAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O
CILAZAPRILAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C2(COc3cccc(Cl)c3)OCCO2)[C@H](O)C[C@@H]1O
Name: LANPROSTON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C2(COc3cccc(Cl)c3)OCCO2)[C@H](O)C[C@@H]1O
Name: LANPROSTON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 494.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 494.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C
Name: DEHYDROCHOLIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C
Name: DEHYDROCHOLIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)[O-])[C@@H]3CC[C@H]2O3)n1.[Na+]
Candidate Name: IFETROBAN SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)[O-])[C@@H]3CC[C@H]2O3)n1.[Na+]
Candidate Name: IFETROBAN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Fc1ccccc1C1=NCCN(CC(F)(F)F)c2ccc(Cl)cc21
FLETAZEPAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Fc1ccccc1C1=NCCN(CC(F)(F)F)c2ccc(Cl)cc21
FLETAZEPAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Drug Name: HYDROCORTISONE VALERATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Drug Name: HYDROCORTISONE VALERATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4",,"## Molecular Property Analysis: ARTEMISININ

### Structure
```
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 282.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 54.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ARTEMISININ

### Structure
```
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 282.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 54.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O
NALOXONE HYDROCHLORIDE DIHYDRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O
NALOXONE HYDROCHLORIDE DIHYDRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12
ABEXINOSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12
ABEXINOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl
Name: CHLORTETRACYCLINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 515.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl
Name: CHLORTETRACYCLINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 515.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Oc1ccccc1C(=O)O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Oc1ccccc1C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)OC(C)(C)[C@@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1
Drug Name: LEVORMELOXIFENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)OC(C)(C)[C@@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1
Drug Name: LEVORMELOXIFENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1.O=C(O)CCC(=O)O
Candidate Name: IFENPRODIL TARTRATE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1.O=C(O)CCC(=O)O
Candidate Name: IFENPRODIL TARTRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C)nc(-n2nc(C)cc2OC)n1
Name: EPIRIZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 234.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C)nc(-n2nc(C)cc2OC)n1
Name: EPIRIZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 234.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cnc(C(=O)O)c[n+]1[O-]
Candidate Name: ACIPIMOX",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 154.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cnc(C(=O)O)c[n+]1[O-]
Candidate Name: ACIPIMOX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 154.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 327.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 327.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCC1CN(C)C(=S)c2cccnc2O1
Name: ROCASTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCC1CN(C)C(=S)c2cccnc2O1
Name: ROCASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(-c2nnc(C)nc2-c2ccc(OC)cc2)cc1
Name: ANITRAZAFEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(-c2nnc(C)nc2-c2ccc(OC)cc2)cc1
Name: ANITRAZAFEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3
APOMORPHINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3
APOMORPHINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C(=O)Nc1nc(-c2ccc(OC)cc2)cs1
Drug Name: TIOXAMAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C(=O)Nc1nc(-c2ccc(OC)cc2)cs1
Drug Name: TIOXAMAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
Candidate Name: AZAMULIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
Candidate Name: AZAMULIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
Name: BOLDENONE UNDECYLENATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
Name: BOLDENONE UNDECYLENATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(=O)oc2cc(OCCN3CCOCC3)cc(OCCN3CCOCC3)c12
Drug Name: MOXICOUMONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(=O)oc2cc(OCCN3CCOCC3)cc(OCCN3CCOCC3)c12
Drug Name: MOXICOUMONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.63 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.63 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1
Candidate Name: FURAZOLIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1
Candidate Name: FURAZOLIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)CCOC(=O)C(NCCN1CCCC1)c1ccccc1
Drug Name: CAMIVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)CCOC(=O)C(NCCN1CCCC1)c1ccccc1
Drug Name: CAMIVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Drug Name: TRIFAROTENE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Drug Name: TRIFAROTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Propose a safer analog of this failed drug:
Vercirnon: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl
Failure reason: Failed to show efficacy in Crohn's disease patients",,"## Structural Improvement Suggestions for Vercirnon

### Original Issue
Failed to show efficacy in Crohn's disease patients

### Recommended Modifications

1. **Reduce Metabolic Liability**
   - Replace metabolically labile groups (e.g., ester ‚Üí amide)
   - Block sites of CYP450 oxidation with fluorine substitution
   - Reduce lipophilicity to minimize reactive metabolite formation

2. **Improve Selectivity**
   - Add stereochemical constraints to reduce off-target binding
   - Modify substituents to exploit differences in target binding sites
   - Use structure-guided design based on target crystal structures

3. **Address Specific Toxicity**
   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk
   - If hepatotoxicity: remove metabolically activated groups
   - If CNS effects: increase polarity to reduce brain penetration

### General Principles
- Maintain target engagement (measure IC50/EC50)
- Improve therapeutic index (efficacy dose vs toxicity dose)
- Consider prodrug strategies for problematic functional groups
",improvement_suggestion,clinical_trial_failures,"<|im_start|>user
Propose a safer analog of this failed drug:
Vercirnon: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl
Failure reason: Failed to show efficacy in Crohn's disease patients
<|im_end|>
<|im_start|>assistant
## Structural Improvement Suggestions for Vercirnon

### Original Issue
Failed to show efficacy in Crohn's disease patients

### Recommended Modifications

1. **Reduce Metabolic Liability**
   - Replace metabolically labile groups (e.g., ester ‚Üí amide)
   - Block sites of CYP450 oxidation with fluorine substitution
   - Reduce lipophilicity to minimize reactive metabolite formation

2. **Improve Selectivity**
   - Add stereochemical constraints to reduce off-target binding
   - Modify substituents to exploit differences in target binding sites
   - Use structure-guided design based on target crystal structures

3. **Address Specific Toxicity**
   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk
   - If hepatotoxicity: remove metabolically activated groups
   - If CNS effects: increase polarity to reduce brain penetration

### General Principles
- Maintain target engagement (measure IC50/EC50)
- Improve therapeutic index (efficacy dose vs toxicity dose)
- Consider prodrug strategies for problematic functional groups

<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1
Candidate Name: TAFAMIDIS MEGLUMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 503.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1
Candidate Name: TAFAMIDIS MEGLUMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 503.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1ccc(/C=N/NC(N)=S)s1
Candidate Name: CITENAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1ccc(/C=N/NC(N)=S)s1
Candidate Name: CITENAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 210.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
DEMANNOSE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
DEMANNOSE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)CCOc1ccc(NC(=S)Nc2ccc(OCCC(C)C)cc2)cc1
TIOCARLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)CCOc1ccc(NC(=S)Nc2ccc(OCCC(C)C)cc2)cc1
TIOCARLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
Candidate Name: MOPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
Candidate Name: MOPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
HYDROXYZINE PAMOATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 763.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
HYDROXYZINE PAMOATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 763.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
Drug Name: CEFDINIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 158.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
Drug Name: CEFDINIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 158.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)c1cn2c(cnc3ccccc32)n1",,"## Molecular Property Analysis: DAZOQUINAST

### Structure
```
O=C(O)c1cn2c(cnc3ccccc32)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 213.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 67.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C(O)c1cn2c(cnc3ccccc32)n1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DAZOQUINAST

### Structure
```
O=C(O)c1cn2c(cnc3ccccc32)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 213.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 67.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
Candidate Name: ARBACLOFEN PLACARBIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
Candidate Name: ARBACLOFEN PLACARBIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
DOXYCYCLINE CALCIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 926.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
DOXYCYCLINE CALCIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 926.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1",,"## Molecular Property Analysis: AZELASTINE

### Structure
```
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 381.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.30 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 38.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: AZELASTINE

### Structure
```
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 381.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.30 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 38.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C#CCN(C)Cc1ccccc1",,"## Molecular Property Analysis: PARGYLINE

### Structure
```
C#CCN(C)Cc1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 159.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C#CCN(C)Cc1ccccc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PARGYLINE

### Structure
```
C#CCN(C)Cc1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 159.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21",,"## Molecular Property Analysis: AMIFLOXACIN

### Structure
```
CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.76 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: AMIFLOXACIN

### Structure
```
CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.76 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCOc1ccc2[nH]c(NC(=O)OC)nc2c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCOc1ccc2[nH]c(NC(=O)OC)nc2c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CO[C@H](C(=O)NO)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)Nc1ccccn1)C(C)(C)C
SOLIMASTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CO[C@H](C(=O)NO)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)Nc1ccccn1)C(C)(C)C
SOLIMASTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl
Candidate Name: MOLINDONE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl
Candidate Name: MOLINDONE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O
Name: FOSLEVODOPA",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O
Name: FOSLEVODOPA
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS
Drug Name: COENZYME_A",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 346.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS
Drug Name: COENZYME_A
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 346.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1
Drug Name: FORMONONETIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1
Drug Name: FORMONONETIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
ILORASERTIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
ILORASERTIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O
Drug Name: THIOTHIXENE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O
Drug Name: THIOTHIXENE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl
Drug Name: CHLORPROMAZINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl
Drug Name: CHLORPROMAZINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1",,"## Molecular Property Analysis: LAPATINIB

### Structure
```
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 581.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.14 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 106.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.180
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: LAPATINIB

### Structure
```
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 581.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.14 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 106.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.180
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O
Drug Name: CAPMATINIB HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O
Drug Name: CAPMATINIB HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(O)c(CC=C(C)C)c(O)c1C(=O)/C=C/c1ccc(O)cc1
Drug Name: XANTHOHUMOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(O)c(CC=C(C)C)c(O)c1C(=O)/C=C/c1ccc(O)cc1
Drug Name: XANTHOHUMOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
Candidate Name: FLAVOXATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
Candidate Name: FLAVOXATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21
Drug Name: BAY-1082439",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 494.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21
Drug Name: BAY-1082439
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 494.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1
Candidate Name: TAPRENEPAG",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1
Candidate Name: TAPRENEPAG
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1.O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(O/N=C(\C(=O)NC1CN(C(=O)NS(=O)(=O)N2CCN(NC(=O)c3cc(=O)c(O)c[nH]3)C2=O)C1=O)c1csc(N)n1)C(=O)O
Name: PIRAZMONAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 684.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 316.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(O/N=C(\C(=O)NC1CN(C(=O)NS(=O)(=O)N2CCN(NC(=O)c3cc(=O)c(O)c[nH]3)C2=O)C1=O)c1csc(N)n1)C(=O)O
Name: PIRAZMONAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 684.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 316.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: [Ca+2].[Cl-].[Cl-]
Drug Name: CALCIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: [Ca+2].[Cl-].[Cl-]
Drug Name: CALCIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 111.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Candidate Name: ATOMOXETINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Candidate Name: ATOMOXETINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21",,"## Molecular Property Analysis: LORMETAZEPAM

### Structure
```
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 335.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.13 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 52.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.870
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: LORMETAZEPAM

### Structure
```
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 335.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.13 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 52.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.870
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N=C(N)NS(=O)(=O)c1ccc(N)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N=C(N)NS(=O)(=O)c1ccc(N)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(OC)c(C(O)C(C)N)c1
Candidate Name: METHOXAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(OC)c(C(O)C(C)N)c1
Candidate Name: METHOXAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(CC)CCC(C)OC(=O)c1ccc(Br)o1.[I-]
FUBROGONIUM IODIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 460.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(CC)CCC(C)OC(=O)c1ccc(Br)o1.[I-]
FUBROGONIUM IODIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 460.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCNCCCCNCCCCNCCCCNCC
Drug Name: DIETHYLHOMOSPERMINE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCNCCCCNCCCCNCCCCNCC
Drug Name: DIETHYLHOMOSPERMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COCCc1ccccn1
METYRIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 137.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 22.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COCCc1ccccn1
METYRIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 137.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 22.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
OXYMESTERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
OXYMESTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C#CC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
PLOMESTANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C#CC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
PLOMESTANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCN[C@@]12C=CC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
Drug Name: PENTAMORPHONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCN[C@@]12C=CC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
Drug Name: PENTAMORPHONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
METHYLPREDNISOLONE ACEPONATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
METHYLPREDNISOLONE ACEPONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
NCCc1ccc(O)c(O)c1",,"## Molecular Property Analysis: DOPAMINE

### Structure
```
NCCc1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 153.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.60 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
NCCc1ccc(O)c(O)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DOPAMINE

### Structure
```
NCCc1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 153.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.60 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC",,"## Molecular Property Analysis: TETROXOPRIM

### Structure
```
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.27 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 114.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TETROXOPRIM

### Structure
```
COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.27 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 114.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(=O)oc2cc(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)ccc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(=O)oc2cc(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)ccc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNc1c(C(=O)OCC)cnc2c1cnn2CC",,"## Molecular Property Analysis: CARTAZOLATE

### Structure
```
CCCCNc1c(C(=O)OCC)cnc2c1cnn2CC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 290.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.84 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 69.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNc1c(C(=O)OCC)cnc2c1cnn2CC
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CARTAZOLATE

### Structure
```
CCCCNc1c(C(=O)OCC)cnc2c1cnn2CC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 290.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.84 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 69.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C(=S)SSC(=S)N(C)C
Drug Name: THIRAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C(=S)SSC(=S)N(C)C
Drug Name: THIRAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCOc1ccccc1Cc1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCOc1ccccc1Cc1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CP(=O)(O)O
FOSFONET",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CP(=O)(O)O
FOSFONET
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 519.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 519.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=C/CCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1
Drug Name: SPIRILENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=C/CCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1
Drug Name: SPIRILENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Drug Name: ENMD-981693",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Drug Name: ENMD-981693
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](/N=C/c3ccco3)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](/N=C/c3ccco3)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"How could Reactive_Met_001 be modified to reduce its toxicity risks?
Original structure: CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl",,"## Structural Improvement Suggestions for Reactive_Met_001

### Original Issue
Formation of reactive quinone-imine metabolite causing hepatotoxicity

### Recommended Modifications

1. **Reduce Metabolic Liability**
   - Replace metabolically labile groups (e.g., ester ‚Üí amide)
   - Block sites of CYP450 oxidation with fluorine substitution
   - Reduce lipophilicity to minimize reactive metabolite formation

2. **Improve Selectivity**
   - Add stereochemical constraints to reduce off-target binding
   - Modify substituents to exploit differences in target binding sites
   - Use structure-guided design based on target crystal structures

3. **Address Specific Toxicity**
   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk
   - If hepatotoxicity: remove metabolically activated groups
   - If CNS effects: increase polarity to reduce brain penetration

### General Principles
- Maintain target engagement (measure IC50/EC50)
- Improve therapeutic index (efficacy dose vs toxicity dose)
- Consider prodrug strategies for problematic functional groups
",improvement_suggestion,clinical_trial_failures,"<|im_start|>user
How could Reactive_Met_001 be modified to reduce its toxicity risks?
Original structure: CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl
<|im_end|>
<|im_start|>assistant
## Structural Improvement Suggestions for Reactive_Met_001

### Original Issue
Formation of reactive quinone-imine metabolite causing hepatotoxicity

### Recommended Modifications

1. **Reduce Metabolic Liability**
   - Replace metabolically labile groups (e.g., ester ‚Üí amide)
   - Block sites of CYP450 oxidation with fluorine substitution
   - Reduce lipophilicity to minimize reactive metabolite formation

2. **Improve Selectivity**
   - Add stereochemical constraints to reduce off-target binding
   - Modify substituents to exploit differences in target binding sites
   - Use structure-guided design based on target crystal structures

3. **Address Specific Toxicity**
   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk
   - If hepatotoxicity: remove metabolically activated groups
   - If CNS effects: increase polarity to reduce brain penetration

### General Principles
- Maintain target engagement (measure IC50/EC50)
- Improve therapeutic index (efficacy dose vs toxicity dose)
- Consider prodrug strategies for problematic functional groups

<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21
Candidate Name: SEMAGACESTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21
Candidate Name: SEMAGACESTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@H](C(=O)N1CCOCC1)N1CC[C@H](NS(=O)(=O)/C=C/c2ccc(Cl)s2)C1=O
Name: GW813893",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 448.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@H](C(=O)N1CCOCC1)N1CC[C@H](NS(=O)(=O)/C=C/c2ccc(Cl)s2)C1=O
Name: GW813893
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 448.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C
Candidate Name: PHA-793887",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C
Candidate Name: PHA-793887
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Name: DIFENOXIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Name: DIFENOXIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
Cc1cc(=O)n(-c2ccccc2)n1C",,"## Molecular Property Analysis: ANTIPYRINE

### Structure
```
Cc1cc(=O)n(-c2ccccc2)n1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 188.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 26.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
Cc1cc(=O)n(-c2ccccc2)n1C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ANTIPYRINE

### Structure
```
Cc1cc(=O)n(-c2ccccc2)n1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 188.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 26.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1
Candidate Name: DIPERODON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1
Candidate Name: DIPERODON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O
Name: FLUVOXAMINE MALEATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O
Name: FLUVOXAMINE MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)c1ccccc1
Drug Name: CLOPIDOGREL BESILATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)c1ccccc1
Drug Name: CLOPIDOGREL BESILATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",,"## Molecular Property Analysis: BETAMETHASONE

### Structure
```
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 392.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 94.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BETAMETHASONE

### Structure
```
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 392.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 94.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Clc1ccccc1C(c1ccc(-c2ccccc2)cc1)n1ccnc1
Candidate Name: LOMBAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Clc1ccccc1C(c1ccc(-c2ccccc2)cc1)n1ccnc1
Candidate Name: LOMBAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
Candidate Name: ENTINOSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
Candidate Name: ENTINOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
BEPRIDIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
BEPRIDIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1(c2ccccc2)OC(C(=O)O)=CC1=O",,"## Molecular Property Analysis: ACIFRAN

### Structure
```
CC1(c2ccccc2)OC(C(=O)O)=CC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 218.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.47 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1(c2ccccc2)OC(C(=O)O)=CC1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ACIFRAN

### Structure
```
CC1(c2ccccc2)OC(C(=O)O)=CC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 218.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.47 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Name: NORETHINDRONE ACETATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Name: NORETHINDRONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",,"## Molecular Property Analysis: VORICONAZOLE

### Structure
```
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 349.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 76.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: VORICONAZOLE

### Structure
```
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 349.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 76.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O
N-ACETYLMANNOSAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O
N-ACETYLMANNOSAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 119.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
GLASDEGIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 374.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
GLASDEGIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 374.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCCCN1CCN(CCN2CCN(C(=O)N(CC)CC)CC2)C1=O
IMPACARZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 493.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCCCN1CCN(CCN2CCN(C(=O)N(CC)CC)CC2)C1=O
IMPACARZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 493.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O
Candidate Name: ZOLPIDEM TARTRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O
Candidate Name: ZOLPIDEM TARTRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1CCC(C)[N+]1(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1
DIMETIPIRIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1CCC(C)[N+]1(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1
DIMETIPIRIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
Drug Name: ERYTHROMYCIN LACTOBIONATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1092.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
Drug Name: ERYTHROMYCIN LACTOBIONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1092.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1c2cccc(O)c2C(=O)c2c(O)cccc21
Name: DANTHRON",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1c2cccc(O)c2C(=O)c2c(O)cccc21
Name: DANTHRON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CN1CCN(CC(=O)O)CCN(C(CO)C(O)CO)CCN(CC(=O)O)CC1
Name: CALCOBUTROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 450.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 185.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CN1CCN(CC(=O)O)CCN(C(CO)C(O)CO)CCN(CC(=O)O)CC1
Name: CALCOBUTROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 450.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 185.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.O=S(=O)(O)O
Name: PACTIMIBE SULFATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 931.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.O=S(=O)(O)O
Name: PACTIMIBE SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 931.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Name: DEFERASIROX",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Name: DEFERASIROX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1CCO1
Drug Name: PROPIOLACTONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 72.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1CCO1
Drug Name: PROPIOLACTONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 72.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN.CS(=O)(=O)O
DEFEROXAMINE MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 656.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 205.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN.CS(=O)(=O)O
DEFEROXAMINE MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 656.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 205.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@H]12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@H]12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I
Drug Name: IOPAMIDOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 188.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I
Drug Name: IOPAMIDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 188.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O
GOLOTIMOD",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O
GOLOTIMOD
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCC(=O)NCCO
Candidate Name: PALMIDROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCC(=O)NCCO
Candidate Name: PALMIDROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Candidate Name: PROCHLORPERAZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Candidate Name: PROCHLORPERAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(OC)cc(N2CCN(C(=O)Nc3nc4cc(F)ccc4nc3OC)CC2)c1
Candidate Name: SUPINOXIN",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(OC)cc(N2CCN(C(=O)Nc3nc4cc(F)ccc4nc3OC)CC2)c1
Candidate Name: SUPINOXIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C=CC1CNCCC1CCC(=O)c1ccnc2ccc(OC)cc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C=CC1CNCCC1CCC(=O)c1ccnc2ccc(OC)cc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccnc([N-]S(=O)(=O)c2ccc(N)cc2)n1.[Na+]
Candidate Name: SULFAMERAZINE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccnc([N-]S(=O)(=O)c2ccc(N)cc2)n1.[Na+]
Candidate Name: SULFAMERAZINE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(C2CNC(=O)C2)cc1OCCCN1CCC(C(=O)c2ccc(F)cc2)CC1
LIDANSERIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(C2CNC(=O)C2)cc1OCCCN1CCC(C(=O)c2ccc(F)cc2)CC1
LIDANSERIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl
Name: ESMOLOL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl
Name: ESMOLOL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
LY-2090314",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
LY-2090314
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 512.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1.O=S(=O)([O-])O
Name: ISAVUCONAZONIUM SULFATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 814.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 159.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1.O=S(=O)([O-])O
Name: ISAVUCONAZONIUM SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 814.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 159.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Drug Name: SUCCINYLSULFATHIAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Drug Name: SUCCINYLSULFATHIAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2ccccc2c1",,"## Molecular Property Analysis: NAPHTHALENE

### Structure
```
c1ccc2ccccc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 128.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.84 | 0-5 | ‚úì |
| H-Bond Acceptors | 0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 0.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.510
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2ccccc2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: NAPHTHALENE

### Structure
```
c1ccc2ccccc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 128.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.84 | 0-5 | ‚úì |
| H-Bond Acceptors | 0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 0.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.510
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CC(O)(CC(=O)O)C(=O)O.[O-][n+]1cccc(/C(Cl)=N/OC[C@H](O)CN2CCCCC2)c1
Candidate Name: ARIMOCLOMOL CITRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CC(O)(CC(=O)O)C(=O)O.[O-][n+]1cccc(/C(Cl)=N/OC[C@H](O)CN2CCCCC2)c1
Candidate Name: ARIMOCLOMOL CITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1
Name: MLN-8054",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1
Name: MLN-8054
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
LEXIBULIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
LEXIBULIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)[C@H](O)C[C@@H]12
Name: EPIMESTROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)[C@H](O)C[C@@H]12
Name: EPIMESTROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C1CCCC1.[Br-]
Name: PENOCTONIUM BROMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C1CCCC1.[Br-]
Name: PENOCTONIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(c1ccc(O)cc1)C(CC)C(C)c1ccc(O)cc1
Candidate Name: BENZESTROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 298.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(c1ccc(O)cc1)C(CC)C(C)c1ccc(O)cc1
Candidate Name: BENZESTROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 298.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12
CEFONICID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 542.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 204.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12
CEFONICID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 542.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 204.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1CC(=O)N2CCSC2=N1
OLPIMEDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 170.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1CC(=O)N2CCSC2=N1
OLPIMEDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 170.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC1=C2CC[C@]3(C)[C@@H](OC(C)=O)CC[C@H]3[C@@H]2CCC1=O
Drug Name: INOCOTERONE ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC1=C2CC[C@]3(C)[C@@H](OC(C)=O)CC[C@H]3[C@@H]2CCC1=O
Drug Name: INOCOTERONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)COC(=O)c1ccc(N)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)COC(=O)c1ccc(N)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(NCCO[N+](=O)[O-])c1cccnc1
Name: NICORANDIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(NCCO[N+](=O)[O-])c1cccnc1
Name: NICORANDIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl",,"## Molecular Property Analysis: HEXACHLOROPHENE

### Structure
```
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 406.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.61 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 40.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: HEXACHLOROPHENE

### Structure
```
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 406.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.61 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 40.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\C(=O)O
Drug Name: CIPRALISANT MALEATE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\C(=O)O
Drug Name: CIPRALISANT MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC
Name: TRIMETHOPRIM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC
Name: TRIMETHOPRIM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Candidate Name: VOGLIBOSE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 153.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Candidate Name: VOGLIBOSE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 153.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C(=O)O)c1ccc(Nc2ccccc2C(=O)O)cc1
Name: ARAPROFEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C(=O)O)c1ccc(Nc2ccccc2C(=O)O)cc1
Name: ARAPROFEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)[C@H](O)[C@@H](O)C(=O)O
Candidate Name: ELIGLUSTAT TARTRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)[C@H](O)[C@@H](O)C(=O)O
Candidate Name: ELIGLUSTAT TARTRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCc1c[nH]c2cccc(O)c12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)CCc1c[nH]c2cccc(O)c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: [N-]=[N+]=O
Drug Name: NITROUS OXIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 44.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: [N-]=[N+]=O
Drug Name: NITROUS OXIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 44.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CC(=O)N/C1=N\P(=O)(O)O
FOSFOCREATININE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CC(=O)N/C1=N\P(=O)(O)O
FOSFOCREATININE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
GOSOGLIPTIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
GOSOGLIPTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O
REMOGLIFLOZIN ETABONATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 522.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O
REMOGLIFLOZIN ETABONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 522.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O
Drug Name: FALDAPREVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 869.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 198.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O
Drug Name: FALDAPREVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 869.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.30 | ‚ö† High (>5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 198.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccc(Cl)cc1)C2
Candidate Name: CLOBENZTROPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccc(Cl)cc1)C2
Candidate Name: CLOBENZTROPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
Name: RENANOLONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
Name: RENANOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]",,"## Molecular Property Analysis: DITERCALINIUM CHLORIDE

### Structure
```
COc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 789.9 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 7.98 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 64.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.150
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DITERCALINIUM CHLORIDE

### Structure
```
COc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 789.9 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 7.98 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 64.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.150
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(CCl)c1ccc(Oc2ccc(C(=O)CCl)cc2)cc1
CLOFENOXYDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(CCl)c1ccc(Oc2ccc(C(=O)CCl)cc2)cc1
CLOFENOXYDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)C(CC(C)N1CCOCC1)(c1ccccc1)c1ccccc1
Name: PHENADOXONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)C(CC(C)N1CCOCC1)(c1ccccc1)c1ccccc1
Name: PHENADOXONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccccc2)n(/N=N/n2c(-c3ccccc3)c(C)[n+]3ccccc23)c2cccc[n+]12.[Br-].[Br-]
Candidate Name: FAZADINIUM BROMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 604.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccccc2)n(/N=N/n2c(-c3ccccc3)c(C)[n+]3ccccc23)c2cccc[n+]12.[Br-].[Br-]
Candidate Name: FAZADINIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 604.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
Drug Name: ALFUZOSIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
Drug Name: ALFUZOSIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1[C@@H](CC(=O)c2ccccc2)CCC[C@H]1C[C@H](O)c1ccccc1
Drug Name: LOBELINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1[C@@H](CC(=O)c2ccccc2)CCC[C@H]1C[C@H](O)c1ccccc1
Drug Name: LOBELINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2c(CCC3CCNCC3)c[nH]c2c1",,"## Molecular Property Analysis: INDALPINE

### Structure
```
c1ccc2c(CCC3CCNCC3)c[nH]c2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 228.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.10 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 27.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2c(CCC3CCNCC3)c[nH]c2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: INDALPINE

### Structure
```
c1ccc2c(CCC3CCNCC3)c[nH]c2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 228.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.10 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 27.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
c1csc(Cc2ccccc2OCC2CNCCO2)c1
Name: TENILOXAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
c1csc(Cc2ccccc2OCC2CNCCO2)c1
Name: TENILOXAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N=C1SCCN1c1ccc(Cl)cc1N",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N=C1SCCN1c1ccc(Cl)cc1N
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O",,"## Molecular Property Analysis: CHLOROGENIC ACID

### Structure
```
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 354.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 6.0 | ‚â§5 | ‚ö† |
| PSA | 164.8 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.230
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CHLOROGENIC ACID

### Structure
```
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 354.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 6.0 | ‚â§5 | ‚ö† |
| PSA | 164.8 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.230
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl
Candidate Name: PROPIOMAZINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl
Candidate Name: PROPIOMAZINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TANDUTINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 562.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TANDUTINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 562.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
OC(c1ccccc1)(c1ccccc1)C1CC1c1ccncc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
OC(c1ccccc1)(c1ccccc1)C1CC1c1ccncc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O
SILYBIN A",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 155.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O
SILYBIN A
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 155.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCn1c(=O)c2nc(C3(N)CCCC3)[nH]c2n(CCC)c1=O
Name: MIDAXIFYLLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCn1c(=O)c2nc(C3(N)CCCC3)[nH]c2n(CCC)c1=O
Name: MIDAXIFYLLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Name: ORLISTAT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 495.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.88 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Name: ORLISTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 495.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.88 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1
EDELINONTRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1
EDELINONTRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1
Candidate Name: APTIGANEL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1
Candidate Name: APTIGANEL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 465.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 465.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)[O-].CC(=O)[O-].[Zn+2]
Name: ZINC ACETATE ANHYDROUS",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 183.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)[O-].CC(=O)[O-].[Zn+2]
Name: ZINC ACETATE ANHYDROUS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 183.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC(C)C1(CCSC)C(=O)NC(=S)NC1=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC(C)C1(CCSC)C(=O)NC(=S)NC1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1
Drug Name: DENIFANSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1
Drug Name: DENIFANSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)CC(O)C(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 134.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)CC(O)C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 134.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(N(CCCC(=O)O)C(=O)c2ccc(Cl)cc2)cc1
Name: CLANOBUTIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(N(CCCC(=O)O)C(=O)c2ccc(Cl)cc2)cc1
Name: CLANOBUTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C
Drug Name: MERICITABINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C
Drug Name: MERICITABINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.Cl
VANCOMYCIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1485.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.Cl
VANCOMYCIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1485.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O
Drug Name: ESTRONE SULFURIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O
Drug Name: ESTRONE SULFURIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1
NEBOGLAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1
NEBOGLAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN(C)CCCN1c2ccccc2Sc2ccccc21",,"## Molecular Property Analysis: PROMAZINE

### Structure
```
CN(C)CCCN1c2ccccc2Sc2ccccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.24 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN(C)CCCN1c2ccccc2Sc2ccccc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PROMAZINE

### Structure
```
CN(C)CCCN1c2ccccc2Sc2ccccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.24 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)c1cc2cc(Cc3cccnc3)ccc2o1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)c1cc2cc(Cc3cccnc3)ccc2o1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1",,"## Molecular Property Analysis: FLUMIZOLE

### Structure
```
COc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 348.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 47.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: FLUMIZOLE

### Structure
```
COc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 348.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 47.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1COc2cccc(OC)c2C1
Candidate Name: ALNESPIRONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1COc2cccc(OC)c2C1
Candidate Name: ALNESPIRONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12.Cl
LUCANTHONE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12.Cl
LUCANTHONE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Candidate Name: SERLOPITANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 555.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Candidate Name: SERLOPITANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 555.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
Candidate Name: FLUNOXAPROFEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
Candidate Name: FLUNOXAPROFEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O
Candidate Name: MOEXIPRIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O
Candidate Name: MOEXIPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 545.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 545.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O
Candidate Name: SOBUZOXANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O
Candidate Name: SOBUZOXANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]",,"## Molecular Property Analysis: TRETAZICAR

### Structure
```
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 252.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.42 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TRETAZICAR

### Structure
```
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 252.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.42 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCC(/C=C/n1ccnc1)OC(=O)c1cccnc1
NICOGRELATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCC(/C=C/n1ccnc1)OC(=O)c1cccnc1
NICOGRELATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl
Drug Name: FINGOLIMOD HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 343.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl
Drug Name: FINGOLIMOD HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 343.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(O)c(Cl)c(C)c1Cl
Name: DICHLOROXYLENOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(O)c(Cl)c(C)c1Cl
Name: DICHLOROXYLENOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1cc2ccccc2o1)c1ccccn1
ETOFURADINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1cc2ccccc2o1)c1ccccn1
ETOFURADINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1",,"## Molecular Property Analysis: FASUDIL

### Structure
```
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 291.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 62.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.900
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: FASUDIL

### Structure
```
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 291.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 62.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.900
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(O)(C(=O)O)P(=O)(O)C(C)(O)C(=O)O
FOSCOLIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(O)(C(=O)O)P(=O)(O)C(C)(O)C(=O)O
FOSCOLIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C
TOSAGESTIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 308.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C
TOSAGESTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 308.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(Oc1ccc(Cl)cc1)C(=O)OC(COC(=O)c1cccnc1)COC(=O)c1cccnc1
Candidate Name: BINIFIBRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(Oc1ccc(Cl)cc1)C(=O)OC(COC(=O)c1cccnc1)COC(=O)c1cccnc1
Candidate Name: BINIFIBRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O
Drug Name: DOPEXAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O
Drug Name: DOPEXAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1
Candidate Name: PIRENPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1
Candidate Name: PIRENPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC1(C(C)C)C(=O)NC(=O)NC1=O
Name: PROBARBITAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 198.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC1(C(C)C)C(=O)NC(=O)NC1=O
Name: PROBARBITAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 198.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc(NC(C)CCCN/C(C)=C2\CCOC2=O)c2ncccc2c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc(NC(C)CCCN/C(C)=C2\CCOC2=O)c2ncccc2c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]
Candidate Name: DIATRIZOATE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 635.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]
Candidate Name: DIATRIZOATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 635.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(/C=C2/C(=O)C3(C)CCC2C3(C)C)cc1
Drug Name: ENZACAMENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(/C=C2/C(=O)C3(C)CCC2C3(C)C)cc1
Drug Name: ENZACAMENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O
Drug Name: TRODUSQUEMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 685.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O
Drug Name: TRODUSQUEMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 685.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C
Drug Name: GAMITHROMYCIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C
Drug Name: GAMITHROMYCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C
Name: PIVAMPICILLIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 463.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C
Name: PIVAMPICILLIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 463.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(O)C(C)(O)c1cccc(Cl)c1
METAGLYCODOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(O)C(C)(O)c1cccc(Cl)c1
METAGLYCODOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1
Candidate Name: NGD-8243",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1
Candidate Name: NGD-8243
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(-c2[nH]c3ccccc3c2-c2ccc(OC)cc2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(-c2[nH]c3ccccc3c2-c2ccc(OC)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1
Name: BITOLTEROL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1
Name: BITOLTEROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C1OC(CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1
FURALTADONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C1OC(CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1
FURALTADONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 136.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 136.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1",,"## Molecular Property Analysis: KETOTIFEN

### Structure
```
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 309.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.01 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.730
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: KETOTIFEN

### Structure
```
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 309.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.01 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.730
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccccc2)nnc1N1CCN(c2ncccn2)CC1
Name: MINOZAC FREE BASE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccccc2)nnc1N1CCN(c2ncccn2)CC1
Name: MINOZAC FREE BASE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
ABIRATERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
ABIRATERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(/C=C/C2=CC(=O)[C@H]3C[C@@H]2C3(C)C)cc(O)c1O
Drug Name: SP-8356",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(/C=C/C2=CC(=O)[C@H]3C[C@@H]2C3(C)C)cc(O)c1O
Drug Name: SP-8356
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 533.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 533.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 513.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 513.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
Name: CHLORPHENIRAMINE MALEATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
Name: CHLORPHENIRAMINE MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13",,"## Molecular Property Analysis: LEVORPHANOL

### Structure
```
CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 257.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.08 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 23.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.770
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: LEVORPHANOL

### Structure
```
CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 257.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.08 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 23.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.770
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(C[S+]([O-])C(c1ccccc1)c1ccccc1)NO
Drug Name: ADRAFINIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(C[S+]([O-])C(c1ccccc1)c1ccccc1)NO
Drug Name: ADRAFINIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=CCSCC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1
Candidate Name: ALTHIAZIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=CCSCC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1
Candidate Name: ALTHIAZIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cccc([C@H]2C[C@@H](N[C@H](C)c3ccccc3)C(=O)N2c2ccc(C(F)(F)F)cc2)c1
Drug Name: MEPPEP",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.91 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cccc([C@H]2C[C@@H](N[C@H](C)c3ccccc3)C(=O)N2c2ccc(C(F)(F)F)cc2)c1
Drug Name: MEPPEP
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.91 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(CCO)CC(=O)[O-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 147.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(CCO)CC(=O)[O-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 147.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2[nH]c(-c3cscn3)nc2c1",,"## Molecular Property Analysis: THIABENDAZOLE

### Structure
```
c1ccc2[nH]c(-c3cscn3)nc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.69 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
c1ccc2[nH]c(-c3cscn3)nc2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: THIABENDAZOLE

### Structure
```
c1ccc2[nH]c(-c3cscn3)nc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.69 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(Br)cc(Br)c(O)c2n1
Candidate Name: BROQUINALDOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(Br)cc(Br)c(O)c2n1
Candidate Name: BROQUINALDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=c1c2ccccc2[se]n1CCn1[se]c2ccccc2c1=O
ETHASELEN",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 422.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=c1c2ccccc2[se]n1CCn1[se]c2ccccc2c1=O
ETHASELEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 422.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)Cc1ccco1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 13.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+](C)(C)Cc1ccco1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 13.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CNCCCN1c2ccccc2CCc2ccccc21",,"## Molecular Property Analysis: DESIPRAMINE

### Structure
```
CNCCCN1c2ccccc2CCc2ccccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 266.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.53 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 15.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CNCCCN1c2ccccc2CCc2ccccc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DESIPRAMINE

### Structure
```
CNCCCN1c2ccccc2CCc2ccccc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 266.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.53 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 15.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
Candidate Name: AMSACRINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
Candidate Name: AMSACRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
Candidate Name: TRYPAN BLUE FREE ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 872.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
Candidate Name: TRYPAN BLUE FREE ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 872.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C.Cl
Name: BACAMPICILLIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 502.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 137.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C.Cl
Name: BACAMPICILLIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 502.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 137.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)OCC(C(=O)O[C@@H]1C[C@@H]2[C@@H]3O[C@H]3[C@H](C1)N2C)c1ccccc1
Name: POSKINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC(=O)OCC(C(=O)O[C@@H]1C[C@@H]2[C@@H]3O[C@H]3[C@H](C1)N2C)c1ccccc1
Name: POSKINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)[C@H](Br)C[C@@H]12
Name: 16.ALPHA.-BROMOEPIANDROSTERONE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)[C@H](Br)C[C@@H]12
Name: 16.ALPHA.-BROMOEPIANDROSTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(Cn1c(Cl)cnc(NCC(F)(F)c2ccccn2)c1=O)NCc1ncccc1F",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(Cn1c(Cl)cnc(NCC(F)(F)c2ccccn2)c1=O)NCc1ncccc1F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Drug Name: AV-101",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Drug Name: AV-101
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NCCOC(c1ccc(F)cc1)c1ccc(Cl)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NCCOC(c1ccc(F)cc1)c1ccc(Cl)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: [Cl-].[Cl-].c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1
Drug Name: HEDAQUINIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 553.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: [Cl-].[Cl-].c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1
Drug Name: HEDAQUINIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 553.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1OC2(CS1)CN1CCC2CC1
Drug Name: CEVIMELINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1OC2(CS1)CN1CCC2CC1
Drug Name: CEVIMELINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc2c(cc1OC)[C@@H]1CN(C)CC[C@@H]1N=C2c1ccc(NC(C)=O)cc1
Candidate Name: BENAFENTRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc2c(cc1OC)[C@@H]1CN(C)CC[C@@H]1N=C2c1ccc(NC(C)=O)cc1
Candidate Name: BENAFENTRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NCc1cc(O)no1
Drug Name: MUSCIMOL",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 114.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NCc1cc(O)no1
Drug Name: MUSCIMOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 114.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1nc2[nH]cnc2c(=S)[nH]1
THIOGUANINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 167.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1nc2[nH]cnc2c(=S)[nH]1
THIOGUANINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 167.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 990.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 201.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 990.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 201.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1c(Cl)c(=O)oc2cc(OP(=O)(OCCCl)OCCCl)ccc12
Drug Name: HALOXON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1c(Cl)c(=O)oc2cc(OP(=O)(OCCCl)OCCCl)ccc12
Drug Name: HALOXON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCOC(=O)c1ccc(N)cc1
BUTAMBEN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCOC(=O)c1ccc(N)cc1
BUTAMBEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1.Cl.Cl
Candidate Name: CEFOTIAM HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1.Cl.Cl
Candidate Name: CEFOTIAM HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1
Name: BROMPERIDOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1
Name: BROMPERIDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1",,"## Molecular Property Analysis: CARZELESIN

### Structure
```
CCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 729.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 9.40 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 135.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CARZELESIN

### Structure
```
CCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 729.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 9.40 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 135.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(C)c1ccc(C(O)CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
TRENIZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(C)c1ccc(C(O)CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
TRENIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Candidate Name: CHOLIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Candidate Name: CHOLIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
Drug Name: SULFADIAZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 250.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
Drug Name: SULFADIAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 250.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl
NARATRIPTAN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl
NARATRIPTAN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1C(=O)CC[C@H]1c1cccnc1
Candidate Name: COTININE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 176.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1C(=O)CC[C@H]1c1cccnc1
Candidate Name: COTININE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 176.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 941.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.43 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 230.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 941.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.43 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 230.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21
QUINELORANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21
QUINELORANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3",,"## Molecular Property Analysis: SANGUINARIUM

### Structure
```
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 332.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.43 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 40.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.370
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: SANGUINARIUM

### Structure
```
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 332.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.43 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 40.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.370
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Nc1c(I)c(NC(=O)CO)c(I)c(C(=O)O)c1I
Candidate Name: IOXOTRIZOIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 629.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Nc1c(I)c(NC(=O)CO)c(I)c(C(=O)O)c1I
Candidate Name: IOXOTRIZOIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 629.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCC(c1ccc(CCCl)cc1)c1c(O)c2ccccc2oc1=O
CLOCOUMAROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.21 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCC(c1ccc(CCCl)cc1)c1c(O)c2ccccc2oc1=O
CLOCOUMAROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.21 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O",,"## Molecular Property Analysis: METHOHEXITAL

### Structure
```
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 262.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.31 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METHOHEXITAL

### Structure
```
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 262.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.31 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(CCO)CC(=O)N(C)c1ccc(Cl)cc1C(=O)c1ccccc1
Drug Name: OXAZAFONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(CCO)CC(=O)N(C)c1ccc(Cl)cc1C(=O)c1ccccc1
Drug Name: OXAZAFONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C
Name: EPELSIBAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 518.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C
Name: EPELSIBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 518.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CNC(=S)C1(c2cccc(C)n2)CCCS1
Candidate Name: LUCARTAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CNC(=S)C1(c2cccc(C)n2)CCCS1
Candidate Name: LUCARTAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
Candidate Name: DAPIPRAZOLE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
Candidate Name: DAPIPRAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O
SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O
SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
Drug Name: STREPTOMYCIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 581.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -8.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 12.0 | ‚ö† High (>5) |
| Polar Surface Area | 336.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
Drug Name: STREPTOMYCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 581.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -8.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 12.0 | ‚ö† High (>5) |
| Polar Surface Area | 336.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1
Candidate Name: HEXETIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1
Candidate Name: HEXETIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=S(=O)(O)CC(S)CS
2,3-DIMERCAPTO-1-PROPANESULFONIC ACID",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=S(=O)(O)CC(S)CS
2,3-DIMERCAPTO-1-PROPANESULFONIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccccc1OCC(O)CNC(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 239.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccccc1OCC(O)CNC(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 239.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN=C(N)NC(=O)Nc1c(C)cccc1C
Name: LIDAMIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 220.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN=C(N)NC(=O)Nc1c(C)cccc1C
Name: LIDAMIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 220.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1ccccc1)c1ccccn1
TRIPELENNAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1ccccc1)c1ccccn1
TRIPELENNAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1
Candidate Name: BENZNIDAZOLE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1
Candidate Name: BENZNIDAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1.[Cl-].[Cl-]
OBIDOXIME CHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1.[Cl-].[Cl-]
OBIDOXIME CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N=C(N)c1ccc(-c2ccc(OC[C@@H]3C[C@@H](CC(=O)O)C(=O)N3)cc2)cc1
Name: FRADAFIBAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N=C(N)c1ccc(-c2ccc(OC[C@@H]3C[C@@H](CC(=O)O)C(=O)N3)cc2)cc1
Name: FRADAFIBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1
Name: EMIXUSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1
Name: EMIXUSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O
LENIOLISIB PHOSPHATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O
LENIOLISIB PHOSPHATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-]
Drug Name: CETALKONIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-]
Drug Name: CETALKONIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
Name: EPERISONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
Name: EPERISONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@]12CC[C@H](O)CC1=CC(=O)C1C2CC[C@]2(C)C(=O)CCC12
7-KETO-DEHYDROEPIANDROSTERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@]12CC[C@H](O)CC1=CC(=O)C1C2CC[C@]2(C)C(=O)CCC12
7-KETO-DEHYDROEPIANDROSTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.Nc1ccc(P(=O)(O)O)cc1.Nc1ccc(P(=O)(O)O)cc1
Name: CHLORHEXIDINE PHOSPHANILATE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 851.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 167.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.Nc1ccc(P(=O)(O)O)cc1.Nc1ccc(P(=O)(O)O)cc1
Name: CHLORHEXIDINE PHOSPHANILATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 851.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 10.0 | ‚ö† High (>5) |
| Polar Surface Area | 167.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C)cc3)CC2)nc2ccccc21
ALINASTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.79 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C)cc3)CC2)nc2ccccc21
ALINASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.79 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=CC(C)NC(=S)NNC(=S)NC
Candidate Name: METHALLIBURE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=CC(C)NC(=S)NNC(=S)NC
Candidate Name: METHALLIBURE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 570.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 570.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl
DEXFENFLURAMINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl
DEXFENFLURAMINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Name: ENZASTAURIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Name: ENZASTAURIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[Se]CC[C@H](N)C(=O)O
Drug Name: SELENOMETHIONINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 196.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[Se]CC[C@H](N)C(=O)O
Drug Name: SELENOMETHIONINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 196.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
[NH-]c1c[n+](N2CCOCC2)no1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 170.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
[NH-]c1c[n+](N2CCOCC2)no1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 170.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1
Drug Name: REPOTRECTINIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1
Drug Name: REPOTRECTINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-]
Candidate Name: METHYLENE BLUE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-]
Candidate Name: METHYLENE BLUE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
Name: RAMIPRIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
Name: RAMIPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CN1C(=O)[C@@H](N[C@@H](CCc2ccccc2)C(=O)O)CCc2ccccc21
BENAZEPRILAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CN1C(=O)[C@@H](N[C@@H](CCc2ccccc2)C(=O)O)CCc2ccccc21
BENAZEPRILAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(O)(CC(=O)O)C1CCCCC1
Candidate Name: CYCLOBUTOIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(O)(CC(=O)O)C1CCCCC1
Candidate Name: CYCLOBUTOIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Candidate Name: OXYBUTYNIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 357.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Candidate Name: OXYBUTYNIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 357.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 134.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 134.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)COc1ccc2c(-c3ccccc3F)noc2c1Br
Candidate Name: BROCRINAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)COc1ccc2c(-c3ccccc3F)noc2c1Br
Candidate Name: BROCRINAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=P(O)(O)OCC(Cl)(Cl)Cl
Name: TRICLOFOS",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 229.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=P(O)(O)OCC(Cl)(Cl)Cl
Name: TRICLOFOS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 229.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 438.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 438.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)NCC(O)c1ccc(O)c2ncccc12
Drug Name: QUINTERENOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)NCC(O)c1ccc(O)c2ncccc12
Drug Name: QUINTERENOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@](C)(O)CC[C@H]3[C@H]1C5
METHYLDIHYDROMORPHINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@](C)(O)CC[C@H]3[C@H]1C5
METHYLDIHYDROMORPHINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(Cc1ccccc1)Cc1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(Cc1ccccc1)Cc1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1
BISOCTRIZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 658.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1
BISOCTRIZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 658.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1C
Name: REPROMICIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 565.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1C
Name: REPROMICIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 565.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Br.COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
Candidate Name: CLOPIDOGREL HYDROBROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Br.COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
Candidate Name: CLOPIDOGREL HYDROBROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Candidate Name: FORMESTANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Candidate Name: FORMESTANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
Name: DEXMETHYLPHENIDATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
Name: DEXMETHYLPHENIDATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
Drug Name: LINEZOLID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
Drug Name: LINEZOLID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(C)c1OCC(C)N.Cl",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 215.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(C)c1OCC(C)N.Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 215.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(CCN2CCN(CCCCOc3ccccc3[C@@]3(C(C)C)Sc4ccccc4N(C)C3=O)CC2)cc(OC)c1OC
Candidate Name: IPROTIAZEM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 647.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cc(CCN2CCN(CCCCOc3ccccc3[C@@]3(C(C)C)Sc4ccccc4N(C)C3=O)CC2)cc(OC)c1OC
Candidate Name: IPROTIAZEM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 647.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1c(C)c2c(c(C)c1OC(=O)COc1ccc(Cl)cc1)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2
TOCOFENOXATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 599.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 10.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1c(C)c2c(c(C)c1OC(=O)COc1ccc(Cl)cc1)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2
TOCOFENOXATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 599.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 10.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Candidate Name: LINAGLIPTIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Candidate Name: LINAGLIPTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 472.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C
Name: BMS-582949",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C
Name: BMS-582949
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)[N-]S(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C.[Na+]
SIMEPREVIR SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 771.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)[N-]S(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C.[Na+]
SIMEPREVIR SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 771.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1",,"## Molecular Property Analysis: MAZAPERTINE

### Structure
```
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 421.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.42 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 36.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MAZAPERTINE

### Structure
```
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 421.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.42 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 36.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
Candidate Name: BUTOXYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
Candidate Name: BUTOXYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
Name: ASTROMICIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 405.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 192.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
Name: ASTROMICIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 405.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 192.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1nccnc1N1CCCCC1
Name: MODALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 177.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1nccnc1N1CCCCC1
Name: MODALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 177.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccccc1OCCOCCOCCN1CCCCC1
Name: GUAIAPATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccccc1OCCOCCOCCN1CCCCC1
Name: GUAIAPATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1
Drug Name: NICERITROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 556.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1
Drug Name: NICERITROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 556.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCOc1ccc(C2SC(=O)NC2=O)cc1OCC
Candidate Name: RISARESTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCOc1ccc(C2SC(=O)NC2=O)cc1OCC
Candidate Name: RISARESTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
Name: SEPROXETINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
Name: SEPROXETINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(C)(C)C(=O)[O-].[Na+]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(C)(C)C(=O)[O-].[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br",,"## Molecular Property Analysis: BRIVUDINE

### Structure
```
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 333.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.46 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 104.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BRIVUDINE

### Structure
```
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 333.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.46 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 104.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.690
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCC(/C=C/n1ccnc1)OCc1ccccc1
Name: MIDAZOGREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCC(/C=C/n1ccnc1)OCc1ccccc1
Name: MIDAZOGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12
Candidate Name: PSILOCYBIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12
Candidate Name: PSILOCYBIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Drug Name: MECLOFENAMATE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 336.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Drug Name: MECLOFENAMATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 336.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl
DONEPEZIL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl
DONEPEZIL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=C\c1ccc(C(=O)O)cc1)c1ccc(C(C)C)s1
Drug Name: NAMIROTENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=C\c1ccc(C(=O)O)cc1)c1ccc(C(C)C)s1
Drug Name: NAMIROTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1
Candidate Name: DNK333",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1
Candidate Name: DNK333
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21",,"## Molecular Property Analysis: DELTA-8-TETRAHYDROCANNABINOL

### Structure
```
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.74 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DELTA-8-TETRAHYDROCANNABINOL

### Structure
```
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.74 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO
Candidate Name: PRINOMASTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 423.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO
Candidate Name: PRINOMASTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 423.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cccc(C)c1N(CCCc1cccnc1)C(=O)[C@@H](C)N
Name: MILACAINIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cccc(C)c1N(CCCc1cccnc1)C(=O)[C@@H](C)N
Name: MILACAINIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1
Drug Name: CLOMIPHENE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1
Drug Name: CLOMIPHENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: FC(F)(F)COCC(F)(F)F
Candidate Name: FLUROTHYL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 182.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: FC(F)(F)COCC(F)(F)F
Candidate Name: FLUROTHYL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 182.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1",,"## Molecular Property Analysis: LOSULAZINE

### Structure
```
O=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 558.6 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 5.28 | 0-5 | ‚ö† |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 82.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.340
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: LOSULAZINE

### Structure
```
O=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 558.6 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 5.28 | 0-5 | ‚ö† |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 82.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.340
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
Name: ARGATROBAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 508.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 177.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
Name: ARGATROBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 508.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 177.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1
Drug Name: LINCOMYCIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1
Drug Name: LINCOMYCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2",,"## Molecular Property Analysis: METESIND

### Structure
```
CN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 436.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 88.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METESIND

### Structure
```
CN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 436.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 88.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.660
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O
Name: DELAVIRDINE MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O
Name: DELAVIRDINE MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCNC(=O)OC1CCN(c2nncc3cc(OC)c(OC)cc23)CC1
Candidate Name: CARBAZERAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCNC(=O)OC1CCN(c2nncc3cc(OC)c(OC)cc23)CC1
Candidate Name: CARBAZERAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 360.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Name: ALFACALCIDOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.59 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Name: ALFACALCIDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.59 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCc1ccccc1NC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)O[C@@H]1N2C
GANSTIGMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCc1ccccc1NC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)O[C@@H]1N2C
GANSTIGMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21",,"## Molecular Property Analysis: AMFONELIC ACID

### Structure
```
CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 308.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 72.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: AMFONELIC ACID

### Structure
```
CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 308.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 72.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC
Candidate Name: LAPAQUISTAT ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 645.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC
Candidate Name: LAPAQUISTAT ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 645.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 131.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2
BIRABRESIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 492.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2
BIRABRESIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 492.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNc1ccc(-c2cc3cc(O)ccc3o2)c(F)n1
Name: FLUTAFURANOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNc1ccc(-c2cc3cc(O)ccc3o2)c(F)n1
Name: FLUTAFURANOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 276.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 276.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1cc(NC(C)CCCN)c2ncccc2c1",,"## Molecular Property Analysis: PRIMAQUINE

### Structure
```
COc1cc(NC(C)CCCN)c2ncccc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 60.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.840
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1cc(NC(C)CCCN)c2ncccc2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PRIMAQUINE

### Structure
```
COc1cc(NC(C)CCCN)c2ncccc2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 60.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.840
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@](Cc1ccc(OP(=O)(O)O)c(O)c1)(NN)C(=O)O
Name: FOSCARBIDOPA",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@](Cc1ccc(OP(=O)(O)O)c(O)c1)(NN)C(=O)O
Name: FOSCARBIDOPA
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CSc1ccccc1OCC(O)CNC(C)C
TIPRENOLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CSc1ccccc1OCC(O)CNC(C)C
TIPRENOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc2c(cc1OCCCF)CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21
Drug Name: FLORBENAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc2c(cc1OCCCF)CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21
Drug Name: FLORBENAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21
ZONAMPANEL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21
ZONAMPANEL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)NC(=O)OC)cc3)cc2)NC1=O
Candidate Name: LEFRADAFIBAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)NC(=O)OC)cc3)cc2)NC1=O
Candidate Name: LEFRADAFIBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)NC)CC(=O)O)CC(=O)O
Name: CALDIAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 419.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 179.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)NC)CC(=O)O)CC(=O)O
Name: CALDIAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 419.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 179.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
MIZOLASTINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
MIZOLASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]
Name: DEXTROTHYROXINE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 816.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]
Name: DEXTROTHYROXINE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 816.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)[C@@H](O)[C@]1(C)O
Name: IDREMCINAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 744.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 165.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)[C@@H](O)[C@]1(C)O
Name: IDREMCINAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 744.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 165.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
O=S(=O)([O-])NC1CCCCC1.[Na+]",,"## Molecular Property Analysis: SODIUM CYCLAMATE

### Structure
```
O=S(=O)([O-])NC1CCCCC1.[Na+]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | nan | 0-5 | ‚ö† |
| H-Bond Acceptors | nan | ‚â§10 | ‚ö† |
| H-Bond Donors | nan | ‚â§5 | ‚ö† |
| PSA | nan √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | nan | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** nan
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
O=S(=O)([O-])NC1CCCCC1.[Na+]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: SODIUM CYCLAMATE

### Structure
```
O=S(=O)([O-])NC1CCCCC1.[Na+]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | nan | 0-5 | ‚ö† |
| H-Bond Acceptors | nan | ‚â§10 | ‚ö† |
| H-Bond Donors | nan | ‚â§5 | ‚ö† |
| PSA | nan √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | nan | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** nan
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc(/C=C/C(=O)O)ccc1OCCO",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc(/C=C/C(=O)O)ccc1OCCO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[Cl-].[Na+]
Name: SODIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 58.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[Cl-].[Na+]
Name: SODIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 58.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1
MAZAPERTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 421.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1
MAZAPERTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 421.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCN/C(=N\CC)NC(=N)N
ETOFORMIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCN/C(=N\CC)NC(=N)N
ETOFORMIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl
Drug Name: Vercirnon",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl
Drug Name: Vercirnon
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O
DORAVIRINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O
DORAVIRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
c1ccc(C2CN=C3NCCN32)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 187.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
c1ccc(C2CN=C3NCCN32)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 187.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",,"## Molecular Property Analysis: AZITHROMYCIN

### Structure
```
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 749.0 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 14.0 | ‚â§10 | ‚ö† |
| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |
| PSA | 180.1 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.240
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: AZITHROMYCIN

### Structure
```
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 749.0 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 14.0 | ‚â§10 | ‚ö† |
| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |
| PSA | 180.1 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.240
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNC1(c2ccccc2Cl)CCCCC1=O
Name: KETAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNC1(c2ccccc2Cl)CCCCC1=O
Name: KETAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]
EVANS BLUE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 960.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]
EVANS BLUE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 960.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N
Name: FURSULTIAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N
Name: FURSULTIAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12
Drug Name: PRINABEREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12
Drug Name: PRINABEREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC1(CC)C(=O)NC(=O)N(C)C1=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 198.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC1(CC)C(=O)NC(=O)N(C)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 198.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)C(=O)Oc1ccc[n+](Cc2ccccc2)c1
BENZPYRINIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)C(=O)Oc1ccc[n+](Cc2ccccc2)c1
BENZPYRINIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)CN1C=CCC(C(N)=O)=C1
Drug Name: CARICOTAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)CN1C=CCC(C(N)=O)=C1
Drug Name: CARICOTAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(c1ccc(F)cc1)C1CCN(CCCn2c(=O)[nH]c3cc(Cl)ccc32)CC1
MILENPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(c1ccc(F)cc1)C1CCN(CCCn2c(=O)[nH]c3cc(Cl)ccc32)CC1
MILENPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N
Drug Name: RIMEPORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N
Drug Name: RIMEPORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1
Drug Name: TAPRENEPAG ISOPROPYL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 520.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1
Drug Name: TAPRENEPAG ISOPROPYL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 520.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23
Candidate Name: ELLAGIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23
Candidate Name: ELLAGIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F
Drug Name: FLUNIXIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F
Drug Name: FLUNIXIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 711.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 235.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 711.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 235.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 191.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 191.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2
Name: ACEPROMAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2
Name: ACEPROMAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
Drug Name: PALBOCICLIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
Drug Name: PALBOCICLIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12C=C(C=O)C(=O)C=C1CC[C@@H]1[C@@H]2[C@H](O)C[C@@]2(C)[C@H]1CC[C@]2(C)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12C=C(C=O)C(=O)C=C1CC[C@@H]1[C@@H]2[C@H](O)C[C@@]2(C)[C@H]1CC[C@]2(C)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl
SARECYCLINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 524.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl
SARECYCLINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 524.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1
Candidate Name: Y-39983",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1
Candidate Name: Y-39983
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21
PARTHENOLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21
PARTHENOLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNC1=NCCc2ccccc21
IQUINDAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNC1=NCCc2ccccc21
IQUINDAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N=C(N)C(O)c1ccc2c(c1)OCO2
OLMIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 194.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N=C(N)C(O)c1ccc2c(c1)OCO2
OLMIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 194.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1
Name: EBROTIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1
Name: EBROTIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CSc1ccc(C(=O)c2cc(CC(=O)O)cc3ccoc23)cc1
Drug Name: TIFURAC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CSc1ccc(C(=O)c2cc(CC(=O)O)cc3ccoc23)cc1
Drug Name: TIFURAC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Name: BROMFENAC",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Name: BROMFENAC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1",,"## Molecular Property Analysis: MICONAZOLE

### Structure
```
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 416.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 27.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MICONAZOLE

### Structure
```
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 416.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 27.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(/C=C/C=C(\C)C(=O)[O-])=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)[O-].[Na+].[Na+]
TRANSCROCETINATE SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(/C=C/C=C(\C)C(=O)[O-])=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)[O-].[Na+].[Na+]
TRANSCROCETINATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2
Name: CARMEGLIPTIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2
Name: CARMEGLIPTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1",,"## Molecular Property Analysis: VANOXERINE

### Structure
```
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 450.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.32 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 15.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: VANOXERINE

### Structure
```
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 450.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.32 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 15.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2
Drug Name: VANZACAFTOR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2
Drug Name: VANZACAFTOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)c1nc(=O)c2cc3cc(OC)c(OC)cc3nc2[nH]1
Name: PIROLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)c1nc(=O)c2cc3cc(OC)c(OC)cc3nc2[nH]1
Name: PIROLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Drug Name: THIARABINE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Drug Name: THIARABINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
Drug Name: GANCICLOVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
Drug Name: GANCICLOVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 255.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O
(+)-SECOISOLARICIRESINOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O
(+)-SECOISOLARICIRESINOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=N/NC(=S)NCCN1CCCCC1)/C(C)=N/NC(=S)NCCN1CCCCC1
Drug Name: BITIPAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=N/NC(=S)NCCN1CCCCC1)/C(C)=N/NC(=S)NCCN1CCCCC1
Drug Name: BITIPAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
ISOPROPICILLIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
ISOPROPICILLIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C/C=C(\C)c1ccc(OC(C)=O)cc1
FENABUTENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 190.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C/C=C(\C)c1ccc(OC(C)=O)cc1
FENABUTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 190.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Candidate Name: TOVORAFENIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Candidate Name: TOVORAFENIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 506.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 195.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 113.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 195.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 113.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1CN1CCN(CCSC(c2ccccc2)c2ccccc2Cl)CC1
BENTIPIMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1CN1CCN(CCSC(c2ccccc2)c2ccccc2Cl)CC1
BENTIPIMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze why Vercirnon was withdrawn/failed and what lessons can be learned:
Structure: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl",,"## Drug Failure Analysis: Vercirnon

### Summary
**Phase Failed:** Phase II
**Year:** 2013.0
**Therapeutic Area:** Immunology
**Failure Category:** Lack of Efficacy

### Detailed Failure Reason

Failed to show efficacy in Crohn's disease patients

### Mechanism of Toxicity

nan

### Efficacy Failure Analysis

**Common Reasons for Efficacy Failure:**
1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology
2. **Patient Population Heterogeneity:** Subgroups may respond differently
3. **Dose Selection:** May not achieve adequate target engagement
4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes

**Prevention Strategies:**
- Extensive target validation using human genetics data
- Biomarker-driven patient stratification
- PK/PD modeling to optimize dosing
- Adaptive trial designs

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy",failure_analysis,clinical_trial_failures,"<|im_start|>user
Analyze why Vercirnon was withdrawn/failed and what lessons can be learned:
Structure: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl
<|im_end|>
<|im_start|>assistant
## Drug Failure Analysis: Vercirnon

### Summary
**Phase Failed:** Phase II
**Year:** 2013.0
**Therapeutic Area:** Immunology
**Failure Category:** Lack of Efficacy

### Detailed Failure Reason

Failed to show efficacy in Crohn's disease patients

### Mechanism of Toxicity

nan

### Efficacy Failure Analysis

**Common Reasons for Efficacy Failure:**
1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology
2. **Patient Population Heterogeneity:** Subgroups may respond differently
3. **Dose Selection:** May not achieve adequate target engagement
4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes

**Prevention Strategies:**
- Extensive target validation using human genetics data
- Biomarker-driven patient stratification
- PK/PD modeling to optimize dosing
- Adaptive trial designs

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](CO)NC(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 551.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.22 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](CO)NC(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 551.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.22 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze why BIIB023 was withdrawn/failed and what lessons can be learned:
Structure: CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2N3CCCC3)OC",,"## Drug Failure Analysis: BIIB023

### Summary
**Phase Failed:** Phase I
**Year:** 2018.0
**Therapeutic Area:** Oncology
**Failure Category:** Safety/Toxicity

### Detailed Failure Reason

Dose-limiting toxicity observed in healthy volunteers

### Mechanism of Toxicity

nan

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy",failure_analysis,clinical_trial_failures,"<|im_start|>user
Analyze why BIIB023 was withdrawn/failed and what lessons can be learned:
Structure: CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2N3CCCC3)OC
<|im_end|>
<|im_start|>assistant
## Drug Failure Analysis: BIIB023

### Summary
**Phase Failed:** Phase I
**Year:** 2018.0
**Therapeutic Area:** Oncology
**Failure Category:** Safety/Toxicity

### Detailed Failure Reason

Dose-limiting toxicity observed in healthy volunteers

### Mechanism of Toxicity

nan

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 276.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 276.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCOC(=O)c1ccc(N(C)C)cc1
Candidate Name: PADIMATE A",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 235.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCOC(=O)c1ccc(N(C)C)cc1
Candidate Name: PADIMATE A
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 235.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: OCC(CO)(CCl)CCl
Drug Name: LOPRODIOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 173.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: OCC(CO)(CCl)CCl
Drug Name: LOPRODIOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 173.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1
Candidate Name: VERDINEXOR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1
Candidate Name: VERDINEXOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1
Drug Name: VARLITINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 466.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1
Drug Name: VARLITINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 466.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1CCC(COC(=O)C(O)(c2ccccc2)c2ccccc2)C1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1CCC(COC(=O)C(O)(c2ccccc2)c2ccccc2)C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@H](N)C(=O)c1ccccc1
CATHINONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 149.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@H](N)C(=O)c1ccccc1
CATHINONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 149.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 598.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 598.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)NS(=O)(=O)c1ccc(N)cc1
Candidate Name: SULFACETAMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)NS(=O)(=O)c1ccc(N)cc1
Candidate Name: SULFACETAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCc1oc2ccccc2c1CC1=NCCN1
COUMAZOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 228.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCc1oc2ccccc2c1CC1=NCCN1
COUMAZOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 228.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CC[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CCOC3=O)CC[C@]12O
Candidate Name: ACTODIGIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CC[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CCOC3=O)CC[C@]12O
Candidate Name: ACTODIGIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNCCCC1(c2ccccc2)SC(C)(C)c2ccccc21
Name: TALSUPRAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNCCCC1(c2ccccc2)SC(C)(C)c2ccccc21
Name: TALSUPRAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(CCc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(C(N)=O)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(CCc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(C(N)=O)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 114.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21",,"## Molecular Property Analysis: LOMEFLOXACIN

### Structure
```
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 351.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.80 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: LOMEFLOXACIN

### Structure
```
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 351.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.80 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze the ADMET properties of this compound:
COc1ccc(O)cc1",,"## Molecular Property Analysis: MEQUINOL

### Structure
```
COc1ccc(O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 124.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.40 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
COc1ccc(O)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MEQUINOL

### Structure
```
COc1ccc(O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 124.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.40 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.610
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
REMDESIVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
REMDESIVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)c1c(C)n(C)c2ccc(O)cc12
Candidate Name: MECARBINATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)c1c(C)n(C)c2ccc(O)cc12
Candidate Name: MECARBINATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COS(=O)(=O)[O-].C[N+](C)(C)CCOC(c1ccccc1)c1ccccc1
Drug Name: MEFENIDRAMIUM METILSULFATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COS(=O)(=O)[O-].C[N+](C)(C)CCOC(c1ccccc1)c1ccccc1
Drug Name: MEFENIDRAMIUM METILSULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
Name: NIFURIMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
Name: NIFURIMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 238.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1",,"## Molecular Property Analysis: GLYBURIDE

### Structure
```
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 494.0 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.64 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 113.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.520
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GLYBURIDE

### Structure
```
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 494.0 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.64 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 113.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.520
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(Cc2cnc(N3C(=O)c4ccccc4C3=O)nc2N)cc(OC)c1OC
Name: TALMETOPRIM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(Cc2cnc(N3C(=O)c4ccccc4C3=O)nc2N)cc(OC)c1OC
Name: TALMETOPRIM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
c1ccc2c(c1)OCC(C1=NCCN1)O2",,"## Molecular Property Analysis: IDAZOXAN

### Structure
```
c1ccc2c(c1)OCC(C1=NCCN1)O2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 204.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.83 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 42.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
c1ccc2c(c1)OCC(C1=NCCN1)O2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: IDAZOXAN

### Structure
```
c1ccc2c(c1)OCC(C1=NCCN1)O2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 204.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.83 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 42.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=CCS[C@H]12)c1csc(NC(=O)[C@H](C)N)n1
CEFTIZOXIME ALAPIVOXIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 191.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=CCS[C@H]12)c1csc(NC(=O)[C@H](C)N)n1
CEFTIZOXIME ALAPIVOXIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 191.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1CCC[C@@H](O)CCCCCc2cc(O)cc(O)c2C(=O)O1
Drug Name: TALERANOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1CCC[C@@H](O)CCCCCc2cc(O)cc(O)c2C(=O)O1
Drug Name: TALERANOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1n[nH]c2c1N(c1ccccc1)C(=O)CC(=O)N2C
RAZOBAZAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1n[nH]c2c1N(c1ccccc1)C(=O)CC(=O)N2C
RAZOBAZAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12",,"## Molecular Property Analysis: IBUTAMOREN

### Structure
```
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 122.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: IBUTAMOREN

### Structure
```
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 122.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1
Candidate Name: DAREXABAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1
Candidate Name: DAREXABAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(C(C)=O)c1c(I)cc(I)c(OCCOC(C)C(=O)O)c1I",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 673.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(C(C)=O)c1c(I)cc(I)c(OCCOC(C)C(=O)O)c1I
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 673.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 444.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 444.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC
Name: FANTOFARONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 550.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC
Name: FANTOFARONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 550.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NCCCCCC(=O)O
Drug Name: AMINOCAPROIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 131.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NCCCCCC(=O)O
Drug Name: AMINOCAPROIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 131.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Clc1ccccc1-c1nc(-c2ccncc2)no1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Clc1ccccc1-c1nc(-c2ccncc2)no1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 51.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1
DEMECARIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 556.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.76 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1
DEMECARIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 556.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.76 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccc(F)cc1)c1ccc(F)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccc(F)cc1)c1ccc(F)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C
Name: AR-67",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C
Name: AR-67
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1c(C(O)CCc2ccc(O)cc2)c(OCCN2CCCCC2)c(OC)c2occc12
Name: PIPROFUROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 455.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1c(C(O)CCc2ccc(O)cc2)c(OCCN2CCCCC2)c(OC)c2occc12
Name: PIPROFUROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 455.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1ccc(Cl)s1)c1ccccn1
CHLOROTHEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCN(Cc1ccc(Cl)s1)c1ccccn1
CHLOROTHEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 295.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
VERAPAMIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
VERAPAMIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
Candidate Name: CLODRONIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
Candidate Name: CLODRONIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)NCC[C@@]341",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)NCC[C@@]341
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc(=O)c2ccccc2[nH]1
TRANSTORINE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)c1cc(=O)c2ccccc2[nH]1
TRANSTORINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.N
Name: AMMONIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 53.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.N
Name: AMMONIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 53.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Candidate Name: PATIDEGIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Candidate Name: PATIDEGIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21.Cl
VALGANCICLOVIR HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 171.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21.Cl
VALGANCICLOVIR HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 171.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O
Name: BX 471 FREE BASE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O
Name: BX 471 FREE BASE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 434.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: OCCN(CCO)c1nc(-c2ccccc2)c(-c2ccccc2)o1
Drug Name: DITAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: OCCN(CCO)c1nc(-c2ccccc2)c(-c2ccccc2)o1
Drug Name: DITAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12",,"## Molecular Property Analysis: GATIFLOXACIN

### Structure
```
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 375.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.98 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 83.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GATIFLOXACIN

### Structure
```
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 375.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.98 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 83.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C",,"## Molecular Property Analysis: METHAZOLAMIDE

### Structure
```
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.42 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 107.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.640
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METHAZOLAMIDE

### Structure
```
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -1.42 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 107.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.640
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1
Candidate Name: MELPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1
Candidate Name: MELPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
NCc1cc(O)no1",,"## Molecular Property Analysis: MUSCIMOL

### Structure
```
NCc1cc(O)no1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 114.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.16 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 72.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
NCc1cc(O)no1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MUSCIMOL

### Structure
```
NCc1cc(O)no1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 114.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.16 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 72.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)NCC(O)c1ccc(O)c(O)c1",,"## Molecular Property Analysis: ISOPROTERENOL

### Structure
```
CC(C)NCC(O)c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 211.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.13 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.560
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)NCC(O)c1ccc(O)c(O)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ISOPROTERENOL

### Structure
```
CC(C)NCC(O)c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 211.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.13 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.560
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)Cn1cccc1-c1nc(-c2ccc(OC)cc2)c(-c2ccc(OC)cc2)s1
PAMICOGREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 448.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)Cn1cccc1-c1nc(-c2ccc(OC)cc2)c(-c2ccc(OC)cc2)s1
PAMICOGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 448.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O
Drug Name: PENTIFYLLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O
Drug Name: PENTIFYLLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C
Name: TAVAPADON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C
Name: TAVAPADON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O
Candidate Name: DESVENLAFAXINE FUMARATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O
Candidate Name: DESVENLAFAXINE FUMARATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 425.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)n1cc2c3c(cccc31)[C@H]1C[C@@H](C(=O)NC3CCCCC3)CN(C)[C@@H]1C2
Name: AMESERGIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)n1cc2c3c(cccc31)[C@H]1C[C@@H](C(=O)NC3CCCCC3)CN(C)[C@@H]1C2
Name: AMESERGIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1
nan",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1
nan
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(O)C(Cl)(Cl)Cl",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 419.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.32 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(O)C(Cl)(Cl)Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 419.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.32 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1ccc(CCC(O)COc2ccc(C(=O)O)cc2)cc1
Drug Name: LIFIBROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 342.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1ccc(CCC(O)COc2ccc(C(=O)O)cc2)cc1
Drug Name: LIFIBROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 342.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccc(O)cc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 405.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccc(O)cc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 405.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1
Name: LEVOMENOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1
Name: LEVOMENOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2",,"## Molecular Property Analysis: CLIDINIUM

### Structure
```
C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 352.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 46.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CLIDINIUM

### Structure
```
C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 352.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.70 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 46.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(-c2ccc(/N=C/NC(C)C)cc2)c[nH]1
Name: BISFENTIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(-c2ccc(/N=C/NC(C)C)cc2)c[nH]1
Name: BISFENTIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1CCCC1=O",,"## Molecular Property Analysis: METHYLPYRROLIDONE

### Structure
```
CN1CCCC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 99.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 0.24 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.430
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1CCCC1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METHYLPYRROLIDONE

### Structure
```
CN1CCCC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 99.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 0.24 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.430
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O
Name: AMFLUTIZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O
Name: AMFLUTIZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCN(Cc1ccc(CC(C)(C)C)cc1)C(Nc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)=C1C(=O)OC(C)(C)OC1=O
Name: ELDACIMIBE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 634.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCN(Cc1ccc(CC(C)(C)C)cc1)C(Nc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)=C1C(=O)OC(C)(C)OC1=O
Name: ELDACIMIBE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 634.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.12 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C/C(=N/Oc5ccc([N+](=O)[O-])cc5)[C@H](Cl)C[C@]4(C)[C@H]3CC[C@]12C
Name: NISTERIME ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 503.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C/C(=N/Oc5ccc([N+](=O)[O-])cc5)[C@H](Cl)C[C@]4(C)[C@H]3CC[C@]12C
Name: NISTERIME ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 503.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Drug Name: PEXIDARTINIB HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Drug Name: PEXIDARTINIB HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NC12CC3CC(CC(C3)C1)C2",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 151.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NC12CC3CC(CC(C3)C1)C2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 151.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl
Drug Name: ALFENTANIL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 453.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl
Drug Name: ALFENTANIL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 453.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Drug Name: OXYCODONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Drug Name: OXYCODONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2
Drug Name: PIPERACETAZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2
Drug Name: PIPERACETAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
Drug Name: PENTAZOCINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
Drug Name: PENTAZOCINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1cc(N)c(/N=N/c2ccc(S(N)(=O)=O)cc2)c(C(=O)O)c1
Candidate Name: SULFACHRYSOIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 174.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1cc(N)c(/N=N/c2ccc(S(N)(=O)=O)cc2)c(C(=O)O)c1
Candidate Name: SULFACHRYSOIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 174.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 397.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Candidate Name: NALMEXONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Candidate Name: NALMEXONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC1(c2ccc(Cl)cc2)CCCCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC1(c2ccc(Cl)cc2)CCCCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1
MMV-048",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1
MMV-048
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21
Name: VELUSETRAG",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21
Name: VELUSETRAG
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)Nc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc3O)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
Name: PIROXICILLIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 672.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 266.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)Nc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc3O)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
Name: PIROXICILLIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 672.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 266.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)CN(CCN2CCN(c3cccc(Cl)c3)C2=O)C1
ZETIDOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)CN(CCN2CCN(c3cccc(Cl)c3)C2=O)C1
ZETIDOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1c(I)cc(I)c(C(=O)N(CCC(=O)O)c2ccccc2)c1I",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 662.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1c(I)cc(I)c(C(=O)N(CCC(=O)O)c2ccccc2)c1I
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 662.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1
Name: INDORAMIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1
Name: INDORAMIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC[C@@H]1CN(c2ccc(OCc3cccc(Cl)c3)cc2)C(=O)O1
ALMOXATONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 346.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC[C@@H]1CN(c2ccc(OCc3cccc(Cl)c3)cc2)C(=O)O1
ALMOXATONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 346.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1
Drug Name: TALOTREXIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 573.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 248.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1
Drug Name: TALOTREXIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 573.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 248.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)NC)c(N)cc1OC
Name: ALPIROPRIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)NC)c(N)cc1OC
Name: ALPIROPRIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 113.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
[Cl-].[K+]
POTASSIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 74.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
[Cl-].[K+]
POTASSIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 74.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(OCCN1CCCCCCC1)(c1ccccc1)c1ccc(Cl)cc1
Drug Name: OCTASTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.89 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(OCCN1CCCCCCC1)(c1ccccc1)c1ccc(Cl)cc1
Drug Name: OCTASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.89 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C=C/C(=O)N(CCC)C(CC)C(=O)N(C)C
Drug Name: CROPROPAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C=C/C(=O)N(CCC)C(CC)C(=O)N(C)C
Drug Name: CROPROPAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Name: SORAFENIB TOSYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 637.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Name: SORAFENIB TOSYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 637.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)C(=S)SC(=S)N(CC)CC
Candidate Name: SULFIRAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)C(=S)SC(=S)N(CC)CC
Candidate Name: SULFIRAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O
Drug Name: ALEGLITAZAR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O
Drug Name: ALEGLITAZAR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1[nH]cnc2ncnc1-2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 135.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1[nH]cnc2ncnc1-2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 135.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Name: AVIBACTAM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Name: AVIBACTAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)NCCOC(=O)C(Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1
Name: HALOFENATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)NCCOC(=O)C(Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1
Name: HALOFENATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1nc(C)ccc1CN1CC1C#N
Name: CIAMEXON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 203.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1nc(C)ccc1CN1CC1C#N
Name: CIAMEXON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 203.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
Drug Name: L-NAME",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
Drug Name: L-NAME
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)CN(C)c1ccccc1C[S+]([O-])c1nc2ccccc2[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)CN(C)c1ccccc1C[S+]([O-])c1nc2ccccc2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: [Xe]
Drug Name: XENON",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 131.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: [Xe]
Drug Name: XENON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 131.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(CCCN1CCN2Cc3[nH]c4ccccc4c3CC2C1)c1ccc(F)cc1
BIRIPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(CCCN1CCN2Cc3[nH]c4ccccc4c3CC2C1)c1ccc(F)cc1
BIRIPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Candidate Name: IVOSIDENIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Candidate Name: IVOSIDENIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC(C(=O)OCCN1CCN(CCOC(=O)C(CC)c2ccccc2)CC1)c1ccccc1
Name: FEBUVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 466.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC(C(=O)OCCN1CCN(CCOC(=O)C(CC)c2ccccc2)CC1)c1ccccc1
Name: FEBUVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 466.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O
Name: ICOSAPENT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O
Name: ICOSAPENT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
[2H]O[2H]
DEUTERIUM OXIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 20.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
[2H]O[2H]
DEUTERIUM OXIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 20.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Oc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1
Name: ARBUTAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Oc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1
Name: ARBUTAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.45 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl/C(=C\n1cncn1)c1ccc(Cl)cc1Cl
LORECLEZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl/C(=C\n1cncn1)c1ccc(Cl)cc1Cl
LORECLEZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl",,"## Molecular Property Analysis: OCTENIDINE HYDROCHLORIDE

### Structure
```
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 623.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 9.63 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 34.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 25.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: OCTENIDINE HYDROCHLORIDE

### Structure
```
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 623.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 9.63 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 34.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 25.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.110
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1C[C@H](CC(C#N)C(N)=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Candidate Name: CIANERGOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1C[C@H](CC(C#N)C(N)=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Candidate Name: CIANERGOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 322.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
CALCIPOTRIENE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 412.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
CALCIPOTRIENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 412.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 437.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1.Cl",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1.Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Clc1cnn(CCCCN2CCN(c3ncccn3)CC2)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Clc1cnn(CCCCN2CCN(c3ncccn3)CC2)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COCC1(CO)C(=O)C2CCN1CC2
EPRENETAPOPT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COCC1(CO)C(=O)C2CCN1CC2
EPRENETAPOPT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 199.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O
Drug Name: BECOCALCIDIOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O
Drug Name: BECOCALCIDIOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C1CNCCN1.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 562.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C1CNCCN1.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 562.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)C2=CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]2(C)Cc2cnoc21
AZASTENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.04 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)C2=CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]2(C)Cc2cnoc21
AZASTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.04 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Name: BROMFENAC SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 766.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Name: BROMFENAC SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 766.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1",,"## Molecular Property Analysis: TIOSPIRONE

### Structure
```
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 440.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.91 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 56.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TIOSPIRONE

### Structure
```
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 440.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.91 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 56.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.500
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OC(c1ccccc1)C1CCCCN1
Candidate Name: LEVOFACETOPERANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OC(c1ccccc1)C1CCCCN1
Candidate Name: LEVOFACETOPERANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 233.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl
FLURAZEPAM HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl
FLURAZEPAM HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl
Drug Name: FLUOXETINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl
Drug Name: FLUOXETINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccc(C(=O)Cc2ccccc2)cc1C(=O)O
Drug Name: Bromfenac (Duract)",,"## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccc(C(=O)Cc2ccccc2)cc1C(=O)O
Drug Name: Bromfenac (Duract)
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Drug Name: DIFENOXIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Drug Name: DIFENOXIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN(CCN2CCN(CCCN3c4ccccc4Sc4ccc(Cl)cc43)CC2)C1=O
IMICLOPAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 486.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN(CCN2CCN(CCCN3c4ccccc4Sc4ccc(Cl)cc43)CC2)C1=O
IMICLOPAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 486.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O
Drug Name: ROLOFYLLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O
Drug Name: ROLOFYLLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1
Drug Name: MECLIZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1
Drug Name: MECLIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 391.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.56 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21
Drug Name: VOROZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21
Drug Name: VOROZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
Drug Name: SAXAGLIPTIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
Drug Name: SAXAGLIPTIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccccc1C(=O)N1CC/C(=N\OS(=O)(=O)O)c2ccc(Cl)cc21
Drug Name: ALILUSEM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccccc1C(=O)N1CC/C(=N\OS(=O)(=O)O)c2ccc(Cl)cc21
Drug Name: ALILUSEM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 394.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 96.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc2c(cc1N1CCNCC1)c(=O)c(C(=O)O)cn2C1CC1
Drug Name: Grepafloxacin",,"## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc2c(cc1N1CCNCC1)c(=O)c(C(=O)O)cn2C1CC1
Drug Name: Grepafloxacin
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CC[C@H](NC(=O)N[C@@H](CSCc1ccc(F)cc1)C(=O)O)C(=O)O
Drug Name: DCFBC",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CC[C@H](NC(=O)N[C@@H](CSCc1ccc(F)cc1)C(=O)O)C(=O)O
Drug Name: DCFBC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 153.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1Oc2ccc(Cl)cc2N(CC(O)CO)C1=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1Oc2ccc(Cl)cc2N(CC(O)CO)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCOC(=O)/C(=C\c1ccccc1)c1ccccc1
Name: CINNAMAVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCOC(=O)/C(=C\c1ccccc1)c1ccccc1
Name: CINNAMAVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)c1nnc(NS(=O)(=O)c2ccccc2)s1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)c1nnc(NS(=O)(=O)c2ccccc2)s1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1c2ccccc2nc2ccccc12
AMINACRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 194.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1c2ccccc2nc2ccccc12
AMINACRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 194.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
Name: TRILACICLIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
Name: TRILACICLIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C([O-])[O-].[Li+].[Li+]
Candidate Name: LITHIUM CARBONATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 73.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C([O-])[O-].[Li+].[Li+]
Candidate Name: LITHIUM CARBONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 73.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CS(C)(=O)=O",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 94.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CS(C)(=O)=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 94.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"This drug failed in Post-market. Explain why:
Drug: Valdecoxib (Bextra)
SMILES: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3",,"## Drug Failure Analysis: Valdecoxib (Bextra)

### Summary
**Phase Failed:** Post-market
**Year:** 2005.0
**Therapeutic Area:** Pain/Inflammation
**Failure Category:** Cardiovascular/Dermatological

### Detailed Failure Reason

Serious cardiovascular events and severe skin reactions (Stevens-Johnson syndrome)

### Mechanism of Toxicity

nan

### Cardiovascular Toxicity Analysis

**Key Risk Factors:**
1. **hERG Channel Inhibition:** Many cardiotoxic drugs block the hERG potassium channel, leading to QT prolongation and potentially fatal arrhythmias (Torsades de Pointes)
2. **Prothrombotic Effects:** Selective COX-2 inhibitors reduce prostacyclin production, tipping the balance toward platelet aggregation
3. **Myocardial Stress:** Some drugs cause direct cardiomyocyte damage or increase cardiac workload

**Structural Alerts:**
- Tertiary amines with lipophilic aromatic rings often show hERG liability
- Basic nitrogen at appropriate distance from aromatic system increases hERG risk

**Prevention Strategies:**
- Early hERG screening (patch clamp assays)
- In vivo QT studies in multiple species
- Careful monitoring in clinical trials for PR/QT changes

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy",failure_analysis,clinical_trial_failures,"<|im_start|>user
This drug failed in Post-market. Explain why:
Drug: Valdecoxib (Bextra)
SMILES: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3
<|im_end|>
<|im_start|>assistant
## Drug Failure Analysis: Valdecoxib (Bextra)

### Summary
**Phase Failed:** Post-market
**Year:** 2005.0
**Therapeutic Area:** Pain/Inflammation
**Failure Category:** Cardiovascular/Dermatological

### Detailed Failure Reason

Serious cardiovascular events and severe skin reactions (Stevens-Johnson syndrome)

### Mechanism of Toxicity

nan

### Cardiovascular Toxicity Analysis

**Key Risk Factors:**
1. **hERG Channel Inhibition:** Many cardiotoxic drugs block the hERG potassium channel, leading to QT prolongation and potentially fatal arrhythmias (Torsades de Pointes)
2. **Prothrombotic Effects:** Selective COX-2 inhibitors reduce prostacyclin production, tipping the balance toward platelet aggregation
3. **Myocardial Stress:** Some drugs cause direct cardiomyocyte damage or increase cardiac workload

**Structural Alerts:**
- Tertiary amines with lipophilic aromatic rings often show hERG liability
- Basic nitrogen at appropriate distance from aromatic system increases hERG risk

**Prevention Strategies:**
- Early hERG screening (patch clamp assays)
- In vivo QT studies in multiple species
- Careful monitoring in clinical trials for PR/QT changes

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1
Drug Name: HEDAQUINIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1
Drug Name: HEDAQUINIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: c1ccc2c(c1)cc1n2CCCNC1
Drug Name: AZEPINDOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: c1ccc2c(c1)cc1n2CCCNC1
Drug Name: AZEPINDOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O
Name: ALISKIREN FUMARATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1219.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O
Name: ALISKIREN FUMARATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1219.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(C2=Nc3ccccc3Sc3nccn32)CC1
Name: PENTIAPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCN(C2=Nc3ccccc3Sc3nccn32)CC1
Name: PENTIAPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=C1CC[C@@H]2[C@](C)(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC[C@@]2(C)[C@@H]1CCC1=CCOC1=O
NEOANDROGRAPHOLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=C1CC[C@@H]2[C@](C)(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC[C@@]2(C)[C@@H]1CCC1=CCOC1=O
NEOANDROGRAPHOLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O.O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1
TECOVIRIMAT MONOHYDRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O.O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1
TECOVIRIMAT MONOHYDRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCC(CC1)C(=O)C2=CC=C(C=C2)F
Name: hERG_Failure_001",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCC(CC1)C(=O)C2=CC=C(C=C2)F
Name: hERG_Failure_001
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O.[Na+]
Name: CITICOLINE SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 215.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O.[Na+]
Name: CITICOLINE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 215.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Candidate Name: DESONIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Candidate Name: DESONIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)CC1(C(=O)O)CCCC1
Drug Name: ABITESARTAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)CC1(C(=O)O)CCCC1
Drug Name: ABITESARTAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C1CCC(C)C(c2ccc(O)cc2)C1
Candidate Name: MENFEGOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 232.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)C1CCC(C)C(c2ccc(O)cc2)C1
Candidate Name: MENFEGOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 232.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
Candidate Name: SODIUM LAURYL SULFATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
Candidate Name: SODIUM LAURYL SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
c1csc(C2(N3CCCCC3)CCCCC2)c1",,"## Molecular Property Analysis: TENOCYCLIDINE

### Structure
```
c1csc(C2(N3CCCCC3)CCCCC2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 249.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
c1csc(C2(N3CCCCC3)CCCCC2)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TENOCYCLIDINE

### Structure
```
c1csc(C2(N3CCCCC3)CCCCC2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 249.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCC(O)(c2ccc(F)cc2)C(C(=O)c2ccc(F)cc2)C1
Drug Name: FLAZALONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCC(O)(c2ccc(F)cc2)C(C(=O)c2ccc(F)cc2)C1
Drug Name: FLAZALONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1
XL-418",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 609.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1
XL-418
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 609.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.48 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.48 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1
Candidate Name: PROPANIDID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1
Candidate Name: PROPANIDID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Drug Name: IOXAGLATE MEGLUMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1464.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Drug Name: IOXAGLATE MEGLUMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1464.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12
Candidate Name: PRUVANSERIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12
Candidate Name: PRUVANSERIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
c1cncnc1",,"## Molecular Property Analysis: PYRIMIDINE

### Structure
```
c1cncnc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 80.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 0.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 25.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
c1cncnc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PYRIMIDINE

### Structure
```
c1cncnc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 80.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 0.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 25.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(=O)OCC(C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C)c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(=O)OCC(C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C)c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1CC(OC(=O)C(OC(=O)c2cccnc2)c2ccccc2)CC(C)(C)C1
Name: MICINICATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1CC(OC(=O)C(OC(=O)c2cccnc2)c2ccccc2)CC(C)(C)C1
Name: MICINICATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 381.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])c1ccc(Oc2ccc(N=C=S)cc2)cc1
NITROSCANATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])c1ccc(Oc2ccc(N=C=S)cc2)cc1
NITROSCANATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CNC(C)Cc1ccccc1OC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CNC(C)Cc1ccccc1OC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Name: LY-3009120",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Name: LY-3009120
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ccc2c(c1)CN1C(=O)c3ccccc3C1=N2
DANIQUIDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ccc2c(c1)CN1C(=O)c3ccccc3C1=N2
DANIQUIDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)c(CC(=O)SCc1cccnc1)c(C)n2C(=O)c1ccc(Cl)cc1
Drug Name: PIMETACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 465.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc2c(c1)c(CC(=O)SCc1cccnc1)c(C)n2C(=O)c1ccc(Cl)cc1
Drug Name: PIMETACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 465.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
Candidate Name: FLUCONAZOLE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
Candidate Name: FLUCONAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1",,"## Molecular Property Analysis: REBOXETINE

### Structure
```
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 313.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.19 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 39.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.890
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: REBOXETINE

### Structure
```
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 313.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.19 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 39.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.890
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=c1cc[nH]c(=O)[nH]1",,"## Molecular Property Analysis: URACIL

### Structure
```
O=c1cc[nH]c(=O)[nH]1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 112.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.94 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 65.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=c1cc[nH]c(=O)[nH]1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: URACIL

### Structure
```
O=c1cc[nH]c(=O)[nH]1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 112.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.94 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 65.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.450
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C#C[C@H](CC(=O)OCC)NC(=O)CCC(=O)Nc1ccc(C(=N)N)cc1
XEMILOFIBAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C#C[C@H](CC(=O)OCC)NC(=O)CCC(=O)Nc1ccc(C(=N)N)cc1
XEMILOFIBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1",,"## Molecular Property Analysis: ENGLITAZONE

### Structure
```
O=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 353.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.52 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 55.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.910
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
O=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ENGLITAZONE

### Structure
```
O=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 353.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.52 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 55.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.910
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1.O=S(=O)(O)O
Drug Name: CEFTOLOZANE SULFATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 764.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 302.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1.O=S(=O)(O)O
Drug Name: CEFTOLOZANE SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 764.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 302.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O",,"## Molecular Property Analysis: GRISEOFULVIN

### Structure
```
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 352.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.81 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 71.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GRISEOFULVIN

### Structure
```
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 352.8 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.81 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 71.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(CC(C#N)(c1ccccc1)C(C)C)N(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(CC(C#N)(c1ccccc1)C(C)C)N(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O
Name: PF-00562271",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 507.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O
Name: PF-00562271
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 507.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Candidate Name: DAUNORUBICIN CITRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 719.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 185.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Candidate Name: DAUNORUBICIN CITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 719.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 185.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(=O)C1=C(O)C(C)(C)C(O)=C(Cc2c(OC)cc(O)c(C(=O)CCC)c2O)C1=O
Drug Name: DESASPIDIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCC(=O)C1=C(O)C(C)(C)C(O)=C(Cc2c(OC)cc(O)c(C(=O)CCC)c2O)C1=O
Drug Name: DESASPIDIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
Name: VICRIVIROC MALEATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 649.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
Name: VICRIVIROC MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 649.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
IRSOGLADINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
IRSOGLADINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl
Reactive_Met_001",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl
Reactive_Met_001
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
SERTRALINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
SERTRALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(/C=N/NC(=O)c2ccncc2)c(C(=O)O)c1OC
Drug Name: OPINIAZIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(/C=N/NC(=O)c2ccncc2)c(C(=O)O)c1OC
Drug Name: OPINIAZIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=N\Nc1ccc(S(C)(=O)=O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C
Drug Name: LINAROTENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.28 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C/C(=N\Nc1ccc(S(C)(=O)=O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C
Drug Name: LINAROTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.28 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ccc(Cc2ccc(F)cc2)c(N)n1
SAMPIRTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 217.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ccc(Cc2ccc(F)cc2)c(N)n1
SAMPIRTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 217.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]12CCC(c3ccccc3)(CC1)C(=O)C2
Candidate Name: QUINUCLIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 216.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]12CCC(c3ccccc3)(CC1)C(=O)C2
Candidate Name: QUINUCLIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 216.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(=O)[nH]cc1F",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 129.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(=O)[nH]cc1F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 129.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1
DIFLOXACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1
DIFLOXACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21
Sertraline",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21
Sertraline
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)/C=C\C(=O)O.O=C1Cc2cc3c(CCC4CCN(Cc5ccccc5)CC4)noc3cc2N1
Candidate Name: ICOPEZIL MALEATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 491.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)/C=C\C(=O)O.O=C1Cc2cc3c(CCC4CCN(Cc5ccccc5)CC4)noc3cc2N1
Candidate Name: ICOPEZIL MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 491.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC1(C)CC(=O)NC(=O)C1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 155.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC1(C)CC(=O)NC(=O)C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 155.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
ALPROSTADIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
ALPROSTADIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\C)CCC=C(C)C
GEFARNATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\C)CCC=C(C)C
GEFARNATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 400.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Drug Name: APRICOXIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Drug Name: APRICOXIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 587.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 587.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O.O.O.O.O.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.[Ca+2]
Name: BENZOYLPAS CALCIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 642.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O.O.O.O.O.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.[Ca+2]
Name: BENZOYLPAS CALCIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 642.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Name: TELMISARTAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Name: TELMISARTAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.26 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[Si](C)(C)c1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc([Si](C)(C)C)c1
Drug Name: AMSILAROTENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[Si](C)(C)c1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc([Si](C)(C)C)c1
Drug Name: AMSILAROTENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CCN(C2)[C@@H]13",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CCN(C2)[C@@H]13
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O",,"## Molecular Property Analysis: RILMAKALIM

### Structure
```
CC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 401.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 83.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: RILMAKALIM

### Structure
```
CC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 401.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 83.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
Drug Name: PIPOTIAZINE PALMITATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 714.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 10.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
Drug Name: PIPOTIAZINE PALMITATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 714.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 10.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
Drug Name: TIBOLONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
Drug Name: TIBOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O
DABIGATRAN ETEXILATE MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 723.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.81 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 151.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O
DABIGATRAN ETEXILATE MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 723.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.81 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 151.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOP(=O)(/N=C(\SCCS/C(=N/P(=O)(OCC)OCC)SCc1ccccc1)SCc1ccccc1)OCC
Candidate Name: ZILANTEL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 664.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOP(=O)(/N=C(\SCCS/C(=N/P(=O)(OCC)OCC)SCc1ccccc1)SCc1ccccc1)OCC
Candidate Name: ZILANTEL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 664.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)CCCn1nnnc1-c1ccc2c(c1)[C@@H](Oc1ccc(=O)[nH]n1)[C@](C)(O)C(C)(C)O2
Candidate Name: MAZOKALIM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 154.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOC(=O)CCCn1nnnc1-c1ccc2c(c1)[C@@H](Oc1ccc(=O)[nH]n1)[C@](C)(O)C(C)(C)O2
Candidate Name: MAZOKALIM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 154.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1
ETOMOXIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1
ETOMOXIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1
MARITUPIRDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 304.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 8.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1
MARITUPIRDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 304.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 8.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[AsH3]
Name: ARSENIC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 78.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[AsH3]
Name: ARSENIC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 78.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC.Cl
TIAPRIDE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC.Cl
TIAPRIDE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
Name: ZAFIRLUKAST",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 575.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
Name: ZAFIRLUKAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 575.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
EDOXABAN TOSYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 720.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 136.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
EDOXABAN TOSYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 720.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 136.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O
Drug Name: TELBIVUDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O
Drug Name: TELBIVUDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 242.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2
(-)-EPICATECHIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2
(-)-EPICATECHIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 290.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)COC(=O)CN)cc3)cccc12
Drug Name: LITOMEGLOVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)COC(=O)CN)cc3)cccc12
Drug Name: LITOMEGLOVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 498.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
Drug Name: LATANOPROSTENE BUNOD",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 507.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
Drug Name: LATANOPROSTENE BUNOD
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 507.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1.O.O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 162.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1.O.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 162.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)OCC6CCC[N+]6(C)C)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12.COS(=O)(=O)[O-]
Drug Name: ROXOLONIUM METILSULFATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 694.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)OCC6CCC[N+]6(C)C)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12.COS(=O)(=O)[O-]
Drug Name: ROXOLONIUM METILSULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 694.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(N=[N+]=[N-])cc1
Name: ZIDOMETACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(N=[N+]=[N-])cc1
Name: ZIDOMETACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]
Name: METHSCOPOLAMINE BROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]
Name: METHSCOPOLAMINE BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
DIPHENIDOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
DIPHENIDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=C(C#N)C(=O)OCCCCCCCC
OCRYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 209.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=C(C#N)C(=O)OCCCCCCCC
OCRYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 209.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1",,"## Molecular Property Analysis: ALITRETINOIN

### Structure
```
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 300.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.60 | 0-5 | ‚ö† |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ALITRETINOIN

### Structure
```
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 300.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.60 | 0-5 | ‚ö† |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12
Drug Name: PRALNACASAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 523.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12
Drug Name: PRALNACASAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 523.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+]
Drug Name: PHENYTOIN SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+]
Drug Name: PHENYTOIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 274.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1.[Cl-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1.[Cl-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 273.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1
Name: TEDALINAB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1
Name: TEDALINAB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCOC(C)c1c(C)c2cc3nc(c4c5[nH]c(cc6nc(cc1[nH]2)C(C)=C6CC)c(C)c5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C
Drug Name: HPPH",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 636.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCOC(C)c1c(C)c2cc3nc(c4c5[nH]c(cc6nc(cc1[nH]2)C(C)=C6CC)c(C)c5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C
Drug Name: HPPH
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 636.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.42 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 121.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F",,"## Molecular Property Analysis: FLUCONAZOLE

### Structure
```
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 306.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: FLUCONAZOLE

### Structure
```
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 306.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
Drug Name: GSK-1004723",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 641.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
Drug Name: GSK-1004723
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 641.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.77 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1
Drug Name: TEMOPORFIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 680.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.76 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 138.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1
Drug Name: TEMOPORFIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 680.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.76 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 138.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2[nH]c(SCc3ncc(C)c(OC)c3C)nc2c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2[nH]c(SCc3ncc(C)c(OC)c3C)nc2c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
LUMACAFTOR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
LUMACAFTOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)[O-].C[N+]1(C)[C@@H]2C[C@@H](OC3c4ccccc4CSc4ccccc43)C[C@H]1[C@@H]1O[C@@H]12
Candidate Name: SEVITROPIUM MESILATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)[O-].C[N+]1(C)[C@@H]2C[C@@H](OC3c4ccccc4CSc4ccccc43)C[C@H]1[C@@H]1O[C@@H]12
Candidate Name: SEVITROPIUM MESILATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C
Name: REVAPRAZAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C
Name: REVAPRAZAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O.O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 767.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]
Drug Name: DOXACURIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1106.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]
Drug Name: DOXACURIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1106.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
RALOXIFENE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
RALOXIFENE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@H]3OP(=O)(O)O[C@H]32)c(=O)n1
Drug Name: CIFOSTODINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@H]3OP(=O)(O)O[C@H]32)c(=O)n1
Drug Name: CIFOSTODINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CNC1(c2ccccc2Cl)CCCCC1=O",,"## Molecular Property Analysis: KETAMINE

### Structure
```
CNC1(c2ccccc2Cl)CCCCC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 237.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CNC1(c2ccccc2Cl)CCCCC1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: KETAMINE

### Structure
```
CNC1(c2ccccc2Cl)CCCCC1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 237.7 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.90 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 29.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.860
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCc1cc2ccccc2c(OCCN(C)C)n1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCc1cc2ccccc2c(OCCN(C)C)n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1ccc(Cl)cc1)NS(=O)(=O)c1ccc2c(c1)CCC2
Drug Name: SULOFENUR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Nc1ccc(Cl)cc1)NS(=O)(=O)c1ccc2c(c1)CCC2
Drug Name: SULOFENUR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCc1ncc(C[n+]2ccccc2C)c(N)n1.Cl.[Cl-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCc1ncc(C[n+]2ccccc2C)c(N)n1.Cl.[Cl-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O
Name: PENTETIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 196.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O
Name: PENTETIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 196.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
LOPINAVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 628.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 120.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
LOPINAVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 628.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 120.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O
IBUTAMOREN MESYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O
IBUTAMOREN MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NCCCC(O)(P(=O)(O)O)P(=O)(O)O
ALENDRONIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 161.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NCCCC(O)(P(=O)(O)O)P(=O)(O)O
ALENDRONIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 161.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(=O)(Nc1cccc(OCc2ccc3ccccc3n2)c1)C(F)(F)F
Candidate Name: RITOLUKAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(=O)(Nc1cccc(OCc2ccc3ccccc3n2)c1)C(F)(F)F
Candidate Name: RITOLUKAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl
Name: MILNACIPRAN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl
Name: MILNACIPRAN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C1CCC(CN2CCCCC2)CC1
Name: LEPTACLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C1CCC(CN2CCCCC2)CC1
Name: LEPTACLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O
Drug Name: MECLOCYCLINE SULFOSALICYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 695.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O
Drug Name: MECLOCYCLINE SULFOSALICYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 695.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(C=CC(O)CC(O)CC(=O)O)cc1-c1ccc(F)c(C(C)C)n1
Drug Name: Cerivastatin",,"## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(C=CC(O)CC(O)CC(=O)O)cc1-c1ccc(F)c(C(C)C)n1
Drug Name: Cerivastatin
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1nc[nH]c1CN1CCN(C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](Cc2ccccc2)C1=O
GGTI-2418",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1nc[nH]c1CN1CCN(C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](Cc2ccccc2)C1=O
GGTI-2418
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC
SUXETHONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC
SUXETHONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C
Candidate Name: TASQUINIMOD",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C
Candidate Name: TASQUINIMOD
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 406.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(OC(C)CNC(=N)Cc2cccc(C)c2)c1.Cc1ccc(S(=O)(=O)O)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(OC(C)CNC(=N)Cc2cccc(C)c2)c1.Cc1ccc(S(=O)(=O)O)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 484.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1nnc(SCC2=C(C(=O)OCc3oc(=O)oc3C)N3C(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](C)N)c4ccccc4)[C@H]3SC2)s1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 661.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 197.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1nnc(SCC2=C(C(=O)OCc3oc(=O)oc3C)N3C(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](C)N)c4ccccc4)[C@H]3SC2)s1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 661.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 197.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1
Name: TAZANOLAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1
Name: TAZANOLAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O",,"## Molecular Property Analysis: ATIBEPRONE

### Structure
```
Cc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 330.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.96 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ATIBEPRONE

### Structure
```
Cc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 330.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.96 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C#CCN(C)CC1=Cc2ccccc2Oc2ccccc21",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 275.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C#CCN(C)CC1=Cc2ccccc2Oc2ccccc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 275.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C
Candidate Name: RIBOFLAVIN 5'-PHOSPHATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 208.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C
Candidate Name: RIBOFLAVIN 5'-PHOSPHATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 208.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
[Cl-].[Cl-].[Zn+2]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 136.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
[Cl-].[Cl-].[Zn+2]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 136.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
Nc1cc2[nH]cnc2c(=O)[nH]1",,"## Molecular Property Analysis: DEZAGUANINE

### Structure
```
Nc1cc2[nH]cnc2c(=O)[nH]1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 150.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.17 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 87.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.490
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Nc1cc2[nH]cnc2c(=O)[nH]1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DEZAGUANINE

### Structure
```
Nc1cc2[nH]cnc2c(=O)[nH]1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 150.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.17 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 87.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.490
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC(=O)c1cccc(-c2ccccc2)c1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CCOC(=O)c1cccc(-c2ccccc2)c1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1243.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1243.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.07 | ‚ö† High (>5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
c1cncc([C@@H]2CCCN2)c1",,"## Molecular Property Analysis: NORNICOTINE

### Structure
```
c1cncc([C@@H]2CCCN2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 148.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.51 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 24.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
c1cncc([C@@H]2CCCN2)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: NORNICOTINE

### Structure
```
c1cncc([C@@H]2CCCN2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 148.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 1.51 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 24.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cccnc1NS(=O)(=O)c1ccc(C#Cc2ccc(O)c(C(=O)O)c2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cccnc1NS(=O)(=O)c1ccc(C#Cc2ccc(O)c(C(=O)O)c2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C[N+](C)(C)C)OC(N)=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 161.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C[N+](C)(C)C)OC(N)=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 161.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 167.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 167.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C
AMINOPENTAMIDE SULFATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C
AMINOPENTAMIDE SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[11CH3]Oc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1
Name: JHU-75528 C-11",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[11CH3]Oc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1
Name: JHU-75528 C-11
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)CCO/C(=C1\C2CC3C(C2)C13)c1ccccc1
Candidate Name: TREPTILAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)CCO/C(=C1\C2CC3C(C2)C13)c1ccccc1
Candidate Name: TREPTILAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 105.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2Cl",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C([O-])C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1.[Na+]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.65 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C([O-])C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1.[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.65 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
Drug Name: CYCLAZOCINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
Drug Name: CYCLAZOCINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl
Name: LEVOBUPIVACAINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl
Name: LEVOBUPIVACAINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Br.CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 608.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Br.CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 608.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCC[N+](CCO)(CCO)Cc1ccccc1
Name: BENZOXONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCC[N+](CCO)(CCO)Cc1ccccc1
Name: BENZOXONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)/C=N/NC(=O)c2ccncc2)O[C@@H](CO)[C@H](O)[C@H]1O
Candidate Name: STREPTONIAZID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 700.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -7.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 17.0 | ‚ö† High (>10) |
| H-Bond Donors | 15.0 | ‚ö† High (>5) |
| Polar Surface Area | 368.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)/C=N/NC(=O)c2ccncc2)O[C@@H](CO)[C@H](O)[C@H]1O
Candidate Name: STREPTONIAZID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 700.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -7.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 17.0 | ‚ö† High (>10) |
| H-Bond Donors | 15.0 | ‚ö† High (>5) |
| Polar Surface Area | 368.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1",,"## Molecular Property Analysis: KETOPROFEN

### Structure
```
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 254.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.11 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 54.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: KETOPROFEN

### Structure
```
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 254.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.11 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 54.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.850
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O
Candidate Name: DASATINIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O
Candidate Name: DASATINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1
Name: AZD-1656",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1
Name: AZD-1656
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 478.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 128.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O",,"## Molecular Property Analysis: IOLOPRIDE

### Structure
```
CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 404.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: IOLOPRIDE

### Structure
```
CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 404.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.740
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MOSAPRIDE CITRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 614.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MOSAPRIDE CITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 614.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cccc([C@H](C)c2ncc[nH]2)c1C
DEMIDITRAZ",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cccc([C@H](C)c2ncc[nH]2)c1C
DEMIDITRAZ
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCOC(C)(c1ccccc1)c1ccccn1
Name: DOXYLAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCOC(C)(c1ccccc1)c1ccccn1
Name: DOXYLAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
Name: DUVELISIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
Name: DUVELISIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1
Candidate Name: NONOXYNOL 9",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 616.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1
Candidate Name: NONOXYNOL 9
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 616.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1",,"## Molecular Property Analysis: CETABEN

### Structure
```
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 361.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 7.28 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 17.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.290
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CETABEN

### Structure
```
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 361.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 7.28 | 0-5 | ‚ö† |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 17.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.290
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCN(CCC)C1Cc2cccc3cc(O)cc(c23)C1
ALENTEMOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 283.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCN(CCC)C1Cc2cccc3cc(O)cc(c23)C1
ALENTEMOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 283.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
Candidate Name: OTAMIXABAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
Candidate Name: OTAMIXABAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 446.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Candidate Name: CETIRIZINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Candidate Name: CETIRIZINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 163.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 316.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 163.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCn1nnc([C@H]2O[C@@H](n3cnc4c(N)nc(N[C@H](CO)Cc5ccccc5)nc43)[C@H](O)[C@@H]2O)n1
Name: GW-328267",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCn1nnc([C@H]2O[C@@H](n3cnc4c(N)nc(N[C@H](CO)Cc5ccccc5)nc43)[C@H](O)[C@@H]2O)n1
Name: GW-328267
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
Candidate Name: RATHYRONINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 651.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
Candidate Name: RATHYRONINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 651.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.[Cl-]
Name: PYRVINIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.[Cl-]
Name: PYRVINIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 418.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCc1cc2c(s1)CN[C@@H]1CCc3cc(OC(C)=O)c(OC(C)=O)cc3[C@@H]21
Name: ADROGOLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCc1cc2c(s1)CN[C@@H]1CCc3cc(OC(C)=O)c(OC(C)=O)cc3[C@@H]21
Name: ADROGOLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 399.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: [C-]#[O+]
Drug Name: CARBON MONOXIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 28.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: [C-]#[O+]
Drug Name: CARBON MONOXIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 28.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1cc(CN2CCOCC2)c2cc(O)c(O)cc2o1
Drug Name: FOLESCUTOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=c1cc(CN2CCOCC2)c2cc(O)c(O)cc2o1
Drug Name: FOLESCUTOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 277.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCc1ccc(C(N)=O)nc1
BUPICOMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 178.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCc1ccc(C(N)=O)nc1
BUPICOMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 178.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Drug Name: FLUPREDNISOLONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Drug Name: FLUPREDNISOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCNCC1COc2cccc(OCC)c2O1
Candidate Name: ETHOMOXANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCNCC1COc2cccc(OCC)c2O1
Candidate Name: ETHOMOXANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O
Candidate Name: DISOFENIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O
Candidate Name: DISOFENIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCC(N(Cc2cccs2)c2ccccc2)CC1
THENALIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCC(N(Cc2cccs2)c2ccccc2)CC1
THENALIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 286.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21
Drug Name: RALIMETINIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21
Drug Name: RALIMETINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
Candidate Name: BEPOTASTINE BESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 547.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
Candidate Name: BEPOTASTINE BESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 547.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=c1c(I)c[nH]cc1I
Name: IOPYDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 346.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=c1c(I)c[nH]cc1I
Name: IOPYDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 346.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(CC)COC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1
DENAVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(CC)COC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1
DENAVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
OC(C#CCN1CCCC1)(c1ccccc1)c1ccccc1
Name: BUTINOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
OC(C#CCN1CCCC1)(c1ccccc1)c1ccccc1
Name: BUTINOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCNc1ccc(C(=O)OCCN(C)C)c(O)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCNc1ccc(C(=O)OCCN(C)C)c(O)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O
Drug Name: TAZOFELONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O
Drug Name: TAZOFELONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)S(=O)(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Name: ETISULERGINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)S(=O)(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Name: ETISULERGINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 376.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1",,"## Molecular Property Analysis: PRODIPINE

### Structure
```
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 279.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PRODIPINE

### Structure
```
CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 279.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.48 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC1(c2ccccc2)NC(=O)N(C)C1=O
Drug Name: MEPHENYTOIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC1(c2ccccc2)NC(=O)N(C)C1=O
Drug Name: MEPHENYTOIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl
TERODILINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl
TERODILINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 317.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)c1ccc(NC(=O)c2ccccc2N)c(C)c1
Drug Name: ATOLIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)c1ccc(NC(=O)c2ccccc2N)c(C)c1
Drug Name: ATOLIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)NCC(O)COc1ccccc1C1C[C@@H]2CC[C@H]1C2
Name: BORNAPROLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)NCC(O)COc1ccccc1C1C[C@@H]2CC[C@H]1C2
Name: BORNAPROLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)CN1C(=O)COc2ccccc21
Candidate Name: PARAXAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 206.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)CN1C(=O)COc2ccccc21
Candidate Name: PARAXAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 206.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1
Name: PHENAZOPYRIDINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1
Name: PHENAZOPYRIDINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCc1cccc(CC)c1C(OCCN(C)C)c1ccccn1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCc1cccc(CC)c1C(OCCN(C)C)c1ccccn1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[N+](CC)(CC)CCOc1ccc(/C=C/c2ccccc2)cc1.[I-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[N+](CC)(CC)CCOc1ccc(/C=C/c2ccccc2)cc1.[I-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccnc2c1CCCCC2[S+]([O-])c1nc2ccccc2[nH]1
Candidate Name: NEPAPRAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccnc2c1CCCCC2[S+]([O-])c1nc2ccccc2[nH]1
Candidate Name: NEPAPRAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
O=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O",,"## Molecular Property Analysis: RAFOXANIDE

### Structure
```
O=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 626.0 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.95 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 58.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.310
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
O=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: RAFOXANIDE

### Structure
```
O=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 626.0 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.95 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 58.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.310
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 708.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 170.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 708.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 170.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NCCC[C@](N)(C(=O)O)C(F)F
Name: EFLORNITHINE, (S)-",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 182.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NCCC[C@](N)(C(=O)O)C(F)F
Name: EFLORNITHINE, (S)-
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 182.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.90 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.90 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
Name: Rosiglitazone (Avandia)",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,clinical_trial_failures,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
Name: Rosiglitazone (Avandia)
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
